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ABSTRACT
Hill, Natasha Tremayne. Biomedical Sciences Ph.D. Program, Wright State University
2015. Vitamin D receptor and 1α, 25-dihydroxyvitamin D3 mediated regulation of
ΔNp63α.
1, 25-dihydroxyvitamin D3 (VD3), the ligand for the Vitamin D Receptor
(VDR), functions to both inhibit cell growth and promote cell survival. High-dose VD3 is
being utilized as a cancer preventive therapy for melanoma, breast and colorectal cancers,
without a complete understanding of VD3/VDR signaling. Np63, considered to be a
proto-oncogene, is overexpressed in non-melanoma skin cancers (NMSCs), induces VDR
gene expression and promotes keratinocyte proliferation, and may serve to exacerbate
non-melanoma skin cancer. The objective of this dissertation was to determine whether
VDR/VD3 signaling promotes keratinocyte proliferation by up-regulating Np63. I
showed that VDR increases Np63 expression at both the transcript and protein level.
Furthermore, low doses of VD3 led to increased Np63 protein expression and
keratinocyte proliferation in a VDR-dependent manner, while higher doses of VD3 failed
to increase Np63 expression and instead resulted in reduced proliferation. I found that
VD3-mediated increases in Np63 protein occur partially via activation of Akt.
Simultaneous inhibition of Akt and VDR knockdown blocked the proliferative effects of
low dose VD3 but enhanced the growth suppressive effects of high dose VD3. p38
MAPK was also found to increase Np63 expression in a VD3-dependent manner
leading to increased keratinocyte proliferation. Taken together, my data provided critical
insights into VD3 signaling and bring to light a potentially detrimental effect of VD3
treatment as a chemotherapeutic adjuvant.
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Previous studies have shown that VDR and p63 are overexpressed independently
in NMSC, but no correlation of the two proteins expression has yet been made. Here I
show that increased expression of VDR correlates with overexpression of p63 in a
number of NMSC subtypes. p53 mutant proteins are also expressed in patients with
NMSC. Moreover, mutant p53 was shown to regulate the transcriptional activity of the
VDR, converting the effects of VDR from pro-apoptotic to anti-apoptotic. Here I show
that endogenous VDR and mutant p53 form a complex suggesting they functionally
interact with each other. Furthermore, loss of mutant p53 alone led to a significant
reduction in Np63 transcript and protein levels, while the loss of mutant p53 and VDR
together led to a further reduction in Np63 protein. Loss of mutant p53 abrogated
VD3-mediated increases in Np63 protein, suggesting that mutant p53 is involved in
VD3-mediated increases in Np63 protein expression. Taken together my data suggest
that the absence of mutant p53 could potentially restore VD3 chemotherapeutic potential
in NMSC.
This study provides mechanistic insight into how VD3 can exert both proproliferative and pro-apoptotic effects by elucidating the differential dose effects of VD3
on Np63 protein levels. Delineation of the mechanisms by which VD3 exerts its effect
on Np63 will be critical for determining the future of VD3 in cancer therapies.
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I. INTRODUCTION

A. Non-Melanoma Skin Cancer

Skin cancer is the most commonly occurring cancer in the United States with
approximately 3 million new cases of non-melanoma skin cancer (NMSC) each year
(Rogers et al., 2015). NMSC are classified as squamous cell carcinomas, basal cell
carcinomas, angiosarcoma, cutaneous B-cell lymphoma, cutaneous T-cell lymphoma,
dermatofibrosarcoma protuberans, merkel cell carcinoma, and sebaceous gland
carcinoma. (Boukamp, 2005; Nakayama, 2010). Basal cell carcinoma (BCC) occurs in
the basal layer, which is the deepest layer in the epidermis (Boukamp, 2005; Nakayama,
2010). BCC are slow growing tumors that rarely metastasize and are most frequently
found in fair-skinned individuals (Arlette & Trotter, 2004; Green & Marks, 2004; Chen et
al., 2013; Baheti et al., 2015). Unfortunately, there are no identified precursor lesions for
BCC (Boukamp, 2005; Baheti et al., 2015). Squamous cell carcinomas (SCC) arise in the
squamous cell keratinocytes that make up the outer layers of the epidermis (Boukamp,
2005; Nakayama, 2010). Unlike BCC, there are several known precursor lesions to SCC
(Boukamp, 2005; Ratushny et al., 2012; Rigel & Stein Gold, 2013). The most common
precursor lesion to SCC is Actinic Keratosis (AK) (Ratushny et al., 2012; Rigel & Stein
Gold, 2013). AK lesions are scaly plaques, which are generally pink, tan or brown in
color (Ratushny et al., 2012; Rigel & Stein Gold, 2013). In rare cases AK lesions resolve
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spontaneously, but the majority of AKs lesions lead to SCC (Ratushny et al., 2012; Rigel
& Stein Gold, 2013). Acantholytic Actinic Keratosis (AA) is a variant of AK that has lost
the adhesion proteins, which make up desmosomes, thus leading to a loss of connectivity
between squamous keratinocytes (Goldberg et al., 1994; Barnaby et al., 1997). Another
variant of AK is Bowenoid Actinic Keratosis (BA), which has well defined edges and
generally occurs as a solitary plaque (Goldberg et al., 1994).

Hyperplastic Actinic

Keratosis (HA) is an advanced stage of AK that is similar in appearance to AK but is
thicker in size (Goldberg et al., 1994). SCC in situ, also called Bowen disease, is a
precancerous lesion that can progress to invasive SCC (Goldberg et al., 1994; Ratushny
et al., 2012; Rigel & Stein Gold, 2013). Invasive SCC, especially cases that arise from
tumors on the eyelid, lead to the majority of SCC associated metastases and are
responsible for approximately 3,000 deaths annually (Boukamp, 2005; Nakayama, 2010).
Risk factors for skin cancer include ultraviolet (UV) radiation, inherited
syndromes such as albinism, xeroderma pigmentosum and nevoid basal cell carcinoma, a
weakened immune system, medications such as vandetanib, vemurafenib and
voriconzole, and infection with the human papillomavirus (HPV) (Young, C., 2009;
Gordon, 2013; Surdu, 2014). Most skin cancers are attributed to UV exposure (Young,
C., 2009; Gordon, 2013; Surdu, 2014). UV radiation also induces the production of VD3,
which is an essential nutrient of the body and has been shown to reduce cancer incidence
(Boukamp, 2005; Nakayama, 2010; Reichrath & Reichrath, 2013). Studies have shown
that VD3 prevents NMSC by inhibiting the hedgehog-signaling pathway in BCC and
modulating p53 in SCC (Reichrath & Reichrath, 2013). One of the hallmarks of nonmelanoma skin cancers is an increased expression of the proto-oncogene Np63
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(Bircan et al., 2006; Sakiz et al., 2009), which directly up-regulates the Vitamin D
Receptor (VDR) expression (Kommagani et al., 2009).
B. The Skin
The skin is the largest organ in the body and serves to protect the body from
hazards in the environment (Bikle, 2012). The skin consists of the dermis and epidermis
(Bikle, 2012). The epidermis is where non-melanoma skin cancer arises (Bikle, 2012).
There are 4 layers of the epidermis. The stratum basale or basal layer is the lowest layer
of the epidermis resting on the basal lamina, which separates the epidermis from the
dermis (Bikle, 2012). The stratum basale consists of the basal layer keratinocytes, which
are highly proliferative (Bikle, 2012). These keratinocytes express the highest levels of
Np63 in the skin (Figure 1) (Koster et al., 2004). Characteristic markers of the basal
layer are keratin 5 and keratin 14 (Romano et al., 2012; Giamboi-Miraglia et al., 2015).
The next layer of the epidermis is the stratum spinosum or spinous layer (Figure 1),
which provides structural reinforcement (Bikle, 2012). Characteristic markers of the
spinosum are keratin 1 and keratin 10 (Taylor et al., 2012; Giamboi-Miraglia et al.,
2015). Above the spinosum is the stratum granulosum or granulosum layer, which
functions as a water barrier by preventing water exchange from outside to inside of the
body and vice versa (Figure 1) (Bikle, 2012). A characteristic marker of the granulosum
is loricrin (Giamboi-Miraglia et al., 2015). The outermost layer of the epidermis is the
stratum corneum (Figure 1) (Bikle, 2012). The corneum functions as a barrier between
the body and the outside world (Bikle, 2012). VDR is expressed throughout the epidermis
and plays an important role in the proliferation of the basal layer and differentiation to the
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Figure 1: Cross section of the human epidermis. The epidermis consists of four layers;
the basal layer, spinous layer, the granulosum layer and the corneum. Markers that are
used to define the individual layers are indicated. Np63 is highly expressed in the
basal layer of the epidermis, but decreases as the cell begin to differentiate into the upper
layers of the epidermis.
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spinosum and granulosum (Reichrath & Reichrath, 2013). Np63 is primarily
expressed in the basal layer (Romano et al., 2012). As the epidermis differentiates into
the spinousum and subsequently the granulosum, the expression of Np63 is
dramatically reduced to undetectable levels in upper layer of the epidermis (Koster et al.,
2004).
C. Np63
The transcription factor p63 belongs to the p53 family of proteins (Yang, A. et al.,
1998). p63 contains an N-terminal transactivation domain, a central DNA binding
domain (DBD) and a C-terminal oligomerization domain (Yang, A. et al., 1998), all of
which share high sequence homology with the tumor suppressor p53 (Pagano et al.,
2013). The transcription factor p63 is transcribed from chromosome 3 position q28
(Yang, A. et al., 1998). There are 6 primary isoforms of p63 which arise due to
alternative promoter usage and 3’ splicing (Yang, A. et al., 1998). The p63 gene has two
promoters, the first, known as P1, is located 5’ of exon 1 while the second, known as P2,
is located in intron 3 (Figure 2) (Yang, A. et al., 1998). Use of the P1 promoter drives the
transcription of the TAp63 isoforms with a full-length N-terminal transactivation domain,
whereas use of the internal P2 promoter yields the transcription of the Np63 isoforms
harboring a truncated N-terminal transactivation domain (Figure 2), with 14 unique
amino acids (Yang, A. et al., 1998). Furthermore, differential 3’ splicing of p63 yields ,
β, and γ isoforms of both TAp63 and ΔNp63 proteins (Figure 2) (Yang, A. et al., 1998).
The p63 protein is essential for the formation and proliferation of the epidermis
along with other stratified epithelia, which was clearly demonstrated in p63 null mice
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Figure 2: p63 isoforms. Schematic showing the p63 gene comprising the two promoter
sites, 3’ splicing segments and diagram of the six main p63 isoforms. Transactivation
domain denoted as TA, DNA-binding denoted as DBD, oligomerization domain labeled
as OD, sterile alpha motif denoted SAM and transactivation inhibitory domain labeled as
TI.
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(Mills et al., 1999; Yang, A. et al., 1999). These mice were born lacking skin, limbs and
died shortly after birth due to dehydration (Mills et al., 1999; Yang, A. et al., 1999).
Although TAp63 initiates epithelia stratification, Np63 plays a crucial role in
maintaining epithelial stem cell proliferation (Mills et al., 1999). The most abundant and
physiologically relevant p63 isoform is Np63, which is widely expressed in the basal
layers of stratified epithelium where it primarily functions in maintaining epithelial
integrity (Koster et al., 2004).
Np63 is considered a proto-oncogene and is overexpressed in many cancers
such as basal cell carcinomas (BCC) and squamous cell carcinomas (SCC) (Reis-Filho et
al., 2002; Lo Muzio et al., 2005; Bircan et al., 2006). Mechanistically, the overexpression
of Np63 in cancer has been shown to inhibit the transcription of PTEN leading to
increased tumor cell survival mediated by enhanced AKT activation (Leonard et al.,
2011). Furthermore, Np63 positively regulates the epidermal growth factor receptor,
which has been shown to increase pancreatic cancer cell proliferation (Danilov et al.,
2011). Interestingly, although loss of p63 led to the reduced growth of pancreatic cancer
cells (Danilov et al., 2011), loss of p63 was also shown to increase cancer progression in
prostate, bladder and breast cancer (Medina-Franco et al., 2002; Urist et al., 2002)
indicating a complex role for p63 in mediating cancer progression. Moreover, loss or
inhibition of Np63 is associated with increased motility and cell invasion (Senoo et
al., 2002; Sniezek et al., 2004; Barbieri et al., 2006; Carroll et al., 2006; Kommagani et
al., 2009). Although increased expression of Np63 is considered a biomarker for
Squamous Cell Carcinoma of the lung (Massion et al., 2003), reduced Np63
expression is an indicator of poor prognosis in cancers such as Basal-like Breast
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Carcinomas, Lung Squamous Cell Carcinomas, Lung Adenocarcinomas and Esophagus
Squamous Cell Carcinomas (Graziano & De Laurenzi, 2011). To date, there is little
known about the mechanism that leads to increase or loss of Np63 expression in
cancer. Therefore, this dissertation intends to identify the upstream modulators that lead
to increase Np63 expression.
D. Mutant p53
Several studies have shown that various mutant isoforms of p53 inhibit Np63
activity leading to increased motility (Adorno et al., 2009; Liu et al., 2009; Muller et al.,
2009; Girardini et al., 2011; Liu et al., 2011). The tumor suppressor p53 is transcribed
from the tumor protein p53 (TP53) gene located on the short arm of chromosome 17
locus p13.1 (McBride et al., 1986). The p53 gene location is one of the many sites in the
genome that shows more frequent ultraviolet (UV) induced mutations (Dumaz et al.,
1993; Ziegler et al., 1993). Interestingly, while guanine to thymidine (G-T) mutation are
the most common mutant p53 mutation in lung cancer, cytosine to thymidine (C-T)
mutation which are induced by UV radiation also show a high frequency in lung cancer
(Hainaut & Pfeifer, 2001). The p53 tumor suppressor is a major regulator of cellular
functions such as cell cycle arrest, senescence or apoptosis (Zuckerman et al., 2009).
These functions are prevented in cancer development allowing cells to grow in an
uncontrolled manner (Shaulian et al., 1992; Zuckerman et al., 2009). Interestingly, p53 is
mutated in half of all human cancers, with most non-melanoma skin cancers expressing at
least one mutant allele of p53 (Zuckerman et al., 2009). There are several different types
of p53 mutations, but mutations that alter DNA binding of p53 are the most common
(Freed-Pastor & Prives, 2012). DNA binding domain mutants affect the wild type p53
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function in two ways (Cho et al., 1994). The first mechanism involves mutation of key
residues in the DNA binding domain (DBD) that render the protein incapable of binding
p53 responsive elements (p53RE) in p53 target genes (Pavletich et al., 1993; Cho et al.,
1994; Bullock et al., 1997).These types of mutants are known as contact mutants and
include R248Q, R273C and R282W p53 proteins (Bullock et al., 1997). The second
mechanism in which DNA binding is altered results from a change in the DNA sequence
of p53, which leads to modification in the protein folding of p53 (Cho et al., 1994). These
mutations destabilize the p53 structure and inhibit its binding to its target genes (Cho et
al., 1994; Bullock et al., 1997). The most highly studied of this type of p53 mutant,
known as a conformation mutant, is the p53 R175H protein (Bargonetti et al., 1997; Di
Como et al., 1999; Chicas et al., 2000; Marin et al., 2000; Gaiddon et al., 2001;
Torgeman et al., 2001; Di Agostino et al., 2006; Haupt, S. et al., 2009; Stambolsky et al.,
2010; Liu et al., 2011; Sutherland et al., 2012). While some p53 mutants retain some
residual wild type p53 activity, others inhibit the activity of wild type p53, and/or exhibit
gain of function (GOF) properties (Bargonetti et al., 1997; Di Como et al., 1999; Chicas
et al., 2000; Marin et al., 2000; Gaiddon et al., 2001; Torgeman et al., 2001; Di Agostino
et al., 2006; Haupt, S. et al., 2009; Stambolsky et al., 2010; Liu et al., 2011; Sutherland
et al., 2012). GOF mutant p53 induce cell proliferation, chemoresistance and increase cell
invasion. The six most commonly observed hot spot GOF mutations in p53 occur at sites
R175, G245, R248, R249, R273 and R282 (Harris & Hollstein, 1993; Cho et al., 1994;
Petitjean et al., 2007). These mutations are found in 30% of p53 mutants observed in
human cancers (Harris & Hollstein, 1993; Cho et al., 1994; Petitjean et al., 2007). In
most cases, mutant p53 protein is stable and accumulates in the tumor, which is one of
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Figure 3: Sites and occurrence of p53 mutations. Schematic of p53 gene with the most
evolutionarily conserved sites indicated in blue boxes. The hot spot p53 mutations are
labeled in bold. The p53 mutation found in A431 cells is highlighted in blue and the p53
mutation found in the HaCaT cell line are highlighted in red.
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the hallmarks of cancer (Siegel et al., 2012). Interestingly, the most phylogenetically
conserved residues are the site at which p53 is most heavily mutated (Figure 3) (Harris &
Hollstein, 1993; Cho et al., 1994; Petitjean et al., 2007). One of the most notable
functions of GOF mutant p53 proteins is their ability to inhibit p63 protein function
leading to increased tumor formation and invasion (Girardini et al., 2011; Liu et al.,
2011; Neilsen et al., 2013). Mutant p53 employs multiple mechanisms to promote
tumorigenesis including regulating the activity of its family members wild-type p53, p63
and p73 (Liu et al., 2009; Zuckerman et al., 2009; Girardini et al., 2011; Neilsen et al.,
2013). Both mutant p53 and Np63 have been shown to lead to increased cancer cell
proliferation (Shaulian et al., 1992; Gaiddon et al., 2001; Li, Y. & Prives, 2007; Adorno
et al., 2009; Liu et al., 2009; Marine & Berx, 2009; Muller et al., 2009; Rokaeus et al.,
2010; Girardini et al., 2011; Neilsen et al., 2011; Neilsen et al., 2013). Notably, GOF p53
H179Y has been shown to increase cancer cell proliferation and is expressed in human
keratinocyte cell line HaCaT (Mueller et al., 2001; Yang, D. et al., 2007; Li, X. et al.,
2012). Although, it is not known whether p53 H179Y physically interacts with Np63,
overexpression of p53 H179Y leads to an increase in the cell cycle regulators cyclin A1
and Cdk4 (Yang, D. et al., 2007) thus promoting progression through the cell cycle. A
previous study showed that mutant p53 alters the transactivation of the Vitamin D
Receptor (VDR) such that it inhibits the expression of VDR targets involved in apoptosis
and induces the expression of VDR targets that have the potential to promote
tumorigenesis (Stambolsky et al., 2010). Mutant p53 thereby converts VDR action from
an inducer of apoptosis to an enhancer of cancer cell survival (Stambolsky et al., 2010).
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E. 1α, 25-dihydroxyvitamin D3 (VD3) and VDR
1α, 25-dihydroxyvitamin D3 (VD3) plays major roles in calcium and phosphate
homeostasis in the human body (Bikle, 2012). In cancer and in non-cancerous cells, VD3
induces differentiation and apoptosis (Deeb et al., 2007; Bikle, 2012). The secosteroid
hormone VD3 is produced in the body via the skin or Pre-VD3 is obtained through the diet
and processed in the liver and kidney to produce VD3 (Bikle, 2012). Production of VD3
starts in the skin with the isomerization of 7-dehydrocholesterol to cholecalciferol, which
is induced by UVB radiation at a wavelength between 290-315 nm (Bikle, 2012).
Cholecalciferol (Pre-VD3) exits the skin to produce the active form of VD3 with reactions
that occur in the liver and followed by the kidney or stays in the skin to generate the
biologically active form of VD3 (Bikle, 2012). In the liver or skin, cholecalciferol is
converted to 25α -hydroxyvitamin D3 (calcidiol) by CYP27A1 (Bikle, 2012). Further
conversion to 1α, 25-dihydroxyvitamin D3 (calcitriol) by CYP27B1 occurs in the skin
and kidney (Bikle, 2012). Calcitriol is the biologically active form of VD3 and is
responsible for most of the VD3 induced gene regulation (Bikle, 2012). Calcitriol levels
are down-regulated by its target gene CYP24A, an enzyme that removes the hydroxide at
position 1 to reform calcidiol (Bikle, 2012).
The Vitamin D Receptor (VDR) is a ligand-dependent transcription factor. VD3,
the most biologically active form of Vitamin D, is the ligand that binds VDR (Deeb et al.,
2007; Yang, D. et al., 2007; Haussler et al., 2011). It is unclear if VD3 binds VDR in the
cytoplasm and then moves into the nucleus or if VD3 binds VDR in the nucleus to
regulate gene transcription (Deeb et al., 2007; Yang, D. et al., 2007; Haussler et al.,
2011). In the presence of VD3, VDR heterodimerizes with the retinoic X receptor (RXR)
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Figure 4: VDR/Vitamin D3 Genomic Signaling. Diagram showing VDR and vitamin D
genomic signaling, which results in VD3 target gene transactivation. Transactivation of
VD3 target genes occurs following the binding of VD3 to VDR. This binding leads to
VDR/RXR complex formation and target gene binding near the VDRE.
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Figure 5: Non-genomic VDR/Vitamin D3 signaling. Schematic of VD3 non-genomic
signaling, which shows VD3 can induce the opening of Ca2+ channel, activate GPCR or
lead to the activation of signaling kinase pathways.
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(Deeb et al., 2007; Yang, D. et al., 2007; Haussler et al., 2011). Once in a complex, VDR
binds to the vitamin D response elements (VDRE) in the promoters of its target genes
involved in proliferation and apoptosis to regulate their expression (Figure 4) (Deeb et
al., 2007). VDR is also known to have non-genomic or rapid response activity in the
presence of VD3 (Figure 5) (Haussler et al., 2011). Interestingly, it has been suggested
that the confirmation in which VDR binds VD3 dictates whether VD3/VDR will induce
genomic or non-genomic signaling (Norman et al., 1997; Norman et al., 2002). The nongenomic activity of VD3 leads to the activation of G-proteins, protein kinase C (PKC),
phosphoinositide 3 kinase (PI3K) and phospholipase C (PLC) (Haussler et al., 2011).
VD3 has been explored as an anticancer agent due to its role in apoptosis and
inhibition of angiogenesis (Asagami et al., 1996; Zhao et al., 1997; Iseki et al., 1999;
Chung et al., 2006). Interestingly, VD3 has also been shown to promote survival via
activation of the Akt and p38 MAPK pathway (Zhuang & Burnstein, 1998; Zhang, Y. et
al., 2006; Zhang, X. & Zanello, 2008). Furthermore, increased Akt and p38 MAPK
activation has been shown to increase the expression of Np63 (Barbieri et al., 2003).
Both Akt and p38 MAPK activation by VD3 occur within minutes of VD3 treatment
suggesting that VD3 activates the two kinases via the rapid response pathway (Zhuang &
Burnstein, 1998; Zhang, Y. et al., 2006; Zhang, X. & Zanello, 2008).
F. Akt
Akt, also known as protein kinase B (PKB), is a kinase that inhibits and activates
several cellular processes within mammalian cells leading to increased cell survival
(Altomare & Testa, 2005; Vanhaesebroeck et al., 2012). In addition, Akt can inhibit
apoptosis by preventing the release of cytochrome c from the mitochondria and by

15

inactivating the pro-apoptotic proteins BAD and procaspoase-9 via phosphorylation
(Barbieri et al., 2003; Altomare & Testa, 2005). Another mechanism by which Akt
inhibits apoptosis is through the down-regulation of the tumor suppressor protein p53
(Mayo & Donner, 2002; Zhou & Hung, 2002). This is accomplished by the
phosphorylation of the p53 negative regulator mouse double minute 2 (Mdm2) by Akt
which leads to the stabilization of mdm2, thereby reducing p53 levels. Akt also increases
cell survival by phosphorylation-induced inhibition of cell cycle inhibitors p21 and p27
(Mayo & Donner, 2002; Zhou & Hung, 2002). Furthermore, previous work has shown
that activated Akt leads to an increase in cyclin D1, cyclin D3 and cyclin E, critical for
progression through the cell cycle (Muise-Helmericks et al., 1998). Another mechanism
by which Akt promotes cell survival is by increasing the levels of the proto-oncogene
Np63. More importantly, activated Akt could prove to be a link that connects VD3mediated increase in cell survival with increased expression of ΔNp63α in NMSC.
Akt is expressed as three distinct kinases known as Akt 1 (PKBα), Akt 2 (PKBβ)
and Akt 3 (PKBγ) (Altomare & Testa, 2005; Vanhaesebroeck et al., 2012). These three
Akt kinases are transcribed from three different gene loci but all three of the kinases have
similar functions and are activated in the same manner (Altomare & Testa, 2005;
Vanhaesebroeck et al., 2012). Akt is activated in response to a variety of different
stimuli such as cytokines, growth factors and mitogens (Altomare & Testa, 2005;
Vanhaesebroeck et al., 2012). These stimuli activate a receptor tyrosine kinase (RTK) or
G-protein coupled receptor (GPCR) leading to activation of phosphoinositide-3-kinase
(PI3K) (Altomare & Testa, 2005; Vanhaesebroeck et al., 2012). At the cellular or
nuclear

membrane,

activated

PI3K

phosphorylates

phosphatidylinositol

(3,4)-
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bisphosphate (PI(3,4)P2) to form phosphatidylinositol (3,4,5)-bisphosphate (PI(3,4,5)P3)
(Altomare & Testa, 2005; Vanhaesebroeck et al., 2012). Next, Akt and Phosphoinositidedependent kinase-1 (PDK1) bind PI(3,4,5)P3 via a Pleckstrin homology domain (PH
Domain), a domain that specifically recognizes and binds PI(3,4,5)P3 (Altomare & Testa,
2005; Vanhaesebroeck et al., 2012). Once bound to PI(3,4,5)P3, PDK1 phosphorylates
threonines located at positions 308, 309 and 305 in the kinase domain of Akt1, Akt 2 and
Akt 3, respectively (Altomare & Testa, 2005; Vanhaesebroeck et al., 2012). Following
threonine phosphorylation, mammalian target of rapamycin complex 2 (mTOR2)
phosphorylates Akt on a serine located at the C-terminal regulatory domain leading to
full activation of Akt (positions 473, 474 and 472 for Akt 1, Akt 2 and Akt 3,
respectively) (Altomare & Testa, 2005; Vanhaesebroeck et al., 2012). Once fully
activated, Akt phosphorylates its downstream targets to increase cell survival. A
schematic representation of Akt activation can be found in Figure 6.
G. p38 MAPK
Like Akt, p38 mitogen activated protein kinase (p38 MAPK) is activated in
response to VD3 (Buitrago, C. G. et al., 2006; Buitrago, C. & Boland, 2010).
Furthermore, p38 MAPK activation was shown to increase ΔNp63α protein levels
(Cheng et al., 2009). There are four p38 MAPK proteins, which are transcribed from
different gene loci (Zarubin & Han, 2005; Cuadrado & Nebreda, 2010). The four kinases
share about 60% sequence homology with each other (Zarubin & Han, 2005; Cuadrado &
Nebreda, 2010). They consist of p38α, also referred to as p38, p38β, p38γ and p38δ
(Zarubin & Han, 2005; Cuadrado & Nebreda, 2010). The p38α MAPK is ubiquitously
expressed while p38β, p38γ and p38δ are only expressed in the brain, skeletal muscle and
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Figure 6: AKT signaling pathway. Akt is activated in response to a number of
mitogens. The mitogens bind the receptor tyrosine kinase thereby activating
phosphoinositide-3-kinase. Activation of phosphoinositide-3-kinase then leads to the
conversion of phosphatidylinositol (3,4)-bisphosphate to phosphatidylinositol (3,4,5)bisphosphate. Finally, phosphatidylinositol (3,4,5)-bisphosphate recruits PDK and Akt to
the membrane for full activation of Akt following phosphorylation by PDK and mTOR2.
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endocrine glands, respectively (Zarubin & Han, 2005; Cuadrado & Nebreda, 2010). The
p38 MAPKs have overlapping substrate specificity and therefore up or down-regulates
similar process in the individual tissues where they are expressed (Zarubin & Han, 2005;
Cuadrado & Nebreda, 2010).
p38 is a kinase that regulates several cellular functions including protein
degradation, protein cellular localization, mRNA stability, endocytosis, apoptosis,
cytoskeleton dynamics, proliferation and cell migration (Zarubin & Han, 2005; Cuadrado
& Nebreda, 2010). The mechanism by which p38 MAPK regulate these processes are
diverse and in some cases extremely complex (Zarubin & Han, 2005; Cuadrado &
Nebreda, 2010). For example, p38 MAPK can increase cell proliferation by
phosphorylating the protein known as C-terminal end of membrane-associated
metalloprotease TNFα-converting enzyme, a disintegrin and metalloproteinase domain 17
(TACE/ADAM17) (Cuadrado & Nebreda, 2010). This phosphorylation promotes the
release of transforming growth factor alpha (TGFα) ligand, thereby activating EGFR
signaling. p38 can not only promote proliferation but can also promote apoptosis, cycle
arrest or senescence via the stabilization of its target gene the tumor suppresser p53
(Cuadrado & Nebreda, 2010). The mechanism(s) by which p38 promotes cell
proliferation and cell death are thought to be cell type dependent or dependent on the
method of p38 activation (Cuadrado & Nebreda, 2010). A number of mitogens such as
growth factors, environmental stress and inflammatory cytokines are known to lead to the
activation of p38 MAPK (Zarubin & Han, 2005; Cuadrado & Nebreda, 2010).
The mitogens that activate p38 MAPK signaling pathway all lead to the same
cellular downstream effect, the activation of MAP kinase kinase kinase (MAP3K)
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(Zarubin & Han, 2005; Cuadrado & Nebreda, 2010). There are several known MAP3K
that are upstream of p38 MAPK. They consist of: apoptosis signal-regulating kinase 1
(ASK1), dual-leucine-zipper-bearing kinase 1 (DLK1), TGFβ-activated kinase 1 (TAK1),
thousand-and-one amino acid 1 and 2 (TAO), MAPK / extracellular signal-regulated
kinases kinase 3 and 4 (MEKK3), and leucine zipper and sterile-α motif kinase 1 (ZAK1)
(Zarubin & Han, 2005; Cuadrado & Nebreda, 2010). The MAP3K are serine threonine
kinases, which phosphorylate MAP kinase kinase (MAP2K), specifically MAP kinase
kinase 3 and 6 (MKK3 and MKK6) (Zarubin & Han, 2005; Cuadrado & Nebreda, 2010).
Both MKK3 and MKK6 specifically phosphorylate all p38 MAPK isoforms on in the
activation loop at a threonine glycine tyrosine sequence (Figure 7) (Zarubin & Han, 2005;
Cuadrado & Nebreda, 2010). Additionally, the c-Jun N-terminal kinase (JNK) activator
MKK4 can also activate p38α as shown in Figure 7.
Several studies have shown that VD3/VDR signaling can lead to increased cell
proliferation via activation of the Akt pathway or through the activation of the p38
MAPK signaling pathway (De Haes et al., 2003; Zhang, Y. et al., 2006; Zhang, X. &
Zanello, 2008; Langberg et al., 2009). The mechanism underlying the regulation of
Np63 expression and how this regulation is altered to increase cancer cell proliferation
is poorly understood and very little is known regarding the role of mutant p53 in NMSC.
Furthermore, VDR and VD3 have been implicated in cancer prevention leading to the
need for a better understanding of the mechanism VDR/VD3 utilized to induce either
proliferation or prevent cancer and in what context each phenotype induced. This
dissertation delineates a mechanism by which VDR/VD3 and mutant p53 induce
proliferation through the induction of Np63 and demonstrate that the expression levels
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Figure 7: MAPK p38 signaling pathway. The MAPK p38 is activated by a number of
stimuli, which binds receptor tyrosine kinases leading to the receptors activation.
Following activation, the receptor tyrosine kinase will stimulate the activation of one or
more MAP3Ks (ASK1, DLK1, TAK1, TAO, MEEK and ZAK). The MAP3K will
phosphorylate one or more of the MAP2Ks (MKK3, MKK4 or MKK6) leading to the
activation of the p38 upstream MAP2K. MAP2Ks phosphorylate p38 MAPK leading to
its activation.
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of both Np63 and VDR are elevated in NMSC.
H. Significance
Np63 and mutant p53 are overexpressed in NMSC (Hibi et al., 2000; Choi et
al., 2002; Di Como et al., 2002; Bircan et al., 2006; Sakiz et al., 2009). Furthermore,
mutant p53 downstream targets play a role in the induction of proliferation and inhibition
of apoptosis making mutant p53 harboring cancers problematic to treat. Identification of
pathways that control tumor cell survival in the presence of GOF mutant p53 in cells that
overexpress Np63 remains a major challenge. One method by which mutant p53
action leads to increased proliferation and reduced apoptosis is mutant p53 mediated
inhibitor of p63 transcriptional activity or by the regulating VDR transactivation of VDR
target genes (Gaiddon et al., 2001; Li, Y. et al., 2008; Liu et al., 2009; Stambolsky et al.,
2010; Lin et al., 2012). Our lack of understanding in regards to the mechanism by which
Np63 is increased in a number of cancers makes it extremely difficult to manage
cancers such as NMSC, which regularly reoccur, and express increased levels of
Np63. The work presented herein demonstrates that both VDR and mutant p53 upregulate Np63 protein and transcript expression. Our proposed studies on the
regulation of VDR/VD3 signaling through Np63 will represent novel mechanism by
which VDR/VD3 lead to increased survival. Moreover, since several human cancers have
mutant p53 and elevated Np63, examining the role of mutant p53 on the interplay
between Np63 and VD3 signaling will provide a better understanding of the impact of
VD3 use as a chemotherapeutic agent.
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I. Rationale
Np63 is overexpressed in most non-melanoma skin cancers (NMSCs) (Dumaz
et al., 1993; Ziegler et al., 1993; Hibi et al., 2000; Choi et al., 2002; Di Como et al.,
2002; Bircan et al., 2006; Sakiz et al., 2009). Both Np63 and VDR are expressed in
the basal level of the skin and were independently shown to be increased in nonmelanoma skin cancer (Hibi et al., 2000; Choi et al., 2002; Di Como et al., 2002;
Mitschele et al., 2004; Reichrath et al., 2004; Bircan et al., 2006; Sakiz et al., 2009).
Previous work from our laboratory showed that Np63 transcriptionally up-regulates
the expression of VDR (Kommagani et al., 2006; Kommagani et al., 2009). To date, no
group has investigated whether VDR can in turn up-regulate Np63.

VDR has

genomic and non-genomic functions in the cell (Haussler et al., 2011). The genomic
functions of VDR increases the transcription of its target genes such as CYP27B1 or
CYP24A1 (Haussler et al., 2011). In contrast, the non-genomic functions of VDR lead to
the activation of G-proteins, Protein Kinase C (PKC), Phosphoinositide 3-Kinase (PI3K)
and Phospholipase C (PLC) at the cell membrane (Haussler et al., 2011). Previous studies
have shown that VD3, the VDR ligand, leads to increased activation of both Akt and p38
MAPK (Zhang, Y. et al., 2006; Zhang, X. & Zanello, 2008). Interestingly, both Akt and
p38 MAPK have been shown to positively regulate the expression of Np63 (Ogawa et
al., 2008; Cheng et al., 2009). Thus, VDR and VD3 could potentially increase the
expression of Np63 through Akt or p38 MAPK. Lastly, a report by Stambolsky et al.,
2010 showed mutant p53 can directly interact with VDR in the presence of VD3 to
activate expression of genes that contain the VDR response element (VDRE) in their
promoter regions (HIRA, TGF-β1, CYP24A1 and CYP27B) (Stambolsky et al., 2010).
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Preliminary evidence shows that there are three putative VDRE in the p63 gene promoter
and one immediately downstream of the p63 gene. Thus, mutant p53 could potentially
modulate VDR transcriptional activity to increase the expression of Np63. In this
study I will also test whether mutant p53 increases Np63 gene expression by
modulating VDR.
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II. MATERIALS AND METHODS

A. Cell lines and Reagents
The non-tumorigenic immortalized human keratinocyte HaCaT cell line was
obtained from Dr. Nancy Bigley (Wright State University) while the tumorigenic H-Ras
transformed HaCaT II-4 cells were obtained from Dr. Nancy Colburn (National Cancer
Institute). The squamous cell carcinoma cell line A431 was obtained from ATCC
(Manassas, Virginia, USA). The three cell lines were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 8 % fetal bovine serum (FBS) and 250 U
penicillin and 250 g streptomycin. The human embryonic kidney cell line HEK-293FT
was obtained from Dr. Hakan Cam (Ohio State University). HEK-293FT cells were
maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10 %
fetal bovine serum (FBS), 0.1 mM modified Eagle’s medium non-essential amino acids
(NEAA), 6 mM L-glutamine, 1 mM modified Eagle’s medium sodium pyruvate, 500
μg/mL geneticin and 250 U penicillin and 250 g streptomycin. Neonatal human
epidermal keratinocytes (NHEK) were maintained in KGM-Gold media as per
manufacturer’s instructions (Lonza, Walkersville, MD). The Akt inhibitor MK2206 and
the p38 inhibitor BIRB-796 were purchased from Selleckchem (Houston, TX, USA). The
p38 inhibitor SB202190 was purchased from Cell Signaling (Danvers, MA, USA). 1,
25-dihydroxyvitamin D3 was maintained as a 100 μM stock in 100% ethanol (Cat #
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17936, Sigma-Aldrich, St. Louis, MO). 1, 25-dihydroxyvitamin D3 treatments were
done in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 8% charcoal
stripped fetal bovine serum (FBS) and 250 U penicillin and 250 g streptomycin at a
final EtOH concentration of 0.01%. Charcoal stripped fetal bovine serum was used
because the serum is stripped of all lipophilic molecules such as VD3.
B. mRNA Knockdown
VDR and p63 knockdown studies were conducted in HaCaT, HaCaT II-4, A431
and NHEK cells were performed by two rounds of siRNA transfection using
Lipofectamine RNAi-Max per manufacturer’s instructions (Life Technologies, Carlsbad,
CA, USA). VDR and p63 siRNA used in this study were purchased from Qiagen
(Valencia, CA, USA) and the target sequences used were previously validated
(Kommagani et al., 2009). Knockdown studies of p53 were conducted in HaCaT, HaCaT
II-4 and A431 cells by performing two rounds of siRNA transfection using
Lipofectamine RNAi-Max per manufacturer’s instructions (Life Technologies, Carlsbad,
CA, USA). p53 siRNA used in this study was purchased from Qiagen (Valencia, CA,
USA) against the target sequence 5’-AAFFAAATTGCGTGTGG AGT-3’.
C. Generation of HaCaT stable cell lines via lentivirus infection.
HaCaT-eGFP and HaCaT-Np63 stable cell lines were generated by infection
of the parental HaCaT cells with lentivirus expressing eGFP or Np63 as previously
described (Kommagani et al., 2009). Briefly, virus production was performed using
HEK-293FT cells seeded onto a 10 cm dish at 3x 106 cells per well. Twenty-four hours
later, cells were transfected with 4.6 μg of the HIV-1 gag and pol expressing lentivirus
packing plasmid, 1.8 μg of the HIV-1 rev expressing lentivirus packing plasmid, 2.52 μg
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of the vesicular stomatitis virus G glycoprotein pLP-VSVG plasmid and either 9 μg
pLentiV6-eGFP or pLentiV6-ΔNp63α cDNA using Metafectene (München, Germany).
At 24 hours post infection, HEK-293FT cell media was changed for virus production.
Medium containing virus was collected at 72 hours post transfection, centrifuged to
remove the debris and stored in 1.5 ml aliquots or used immediately to infect HaCaT
cells. To generate stably expressing lines, parental HaCaT cells were seeded at 2x 105
cells per well in two wells of a 6-well dish 24 hours prior to virus infection. The next
day, 1.5 ml of the ΔNp63α or eGFP lentivirus solution, 500 l of complete media and 10
μg/ml of Polybrene (EMD Millipore, Billerica, MA, USA) were added directly to the
parental cells. Lentivirus infected HaCaT cultures were supplemented with fresh media
at 24 hours post infection, and infected cells were subjected to blasticidin (10 mg/ml)
(Life Technologies, Carlsbad, CA USA) selection initiated at 72 hours post-infection to
obtain HaCaT stable cells expressing eGFP or Np63.
D. Cell Immunofluorescence Staining
Cells were grown on sterile glass coverslips and fixed with 2% paraformaldehyde
for 15 min. The coverslips were washed three times with PBS, permeabilized with 0.2%
Triton X-100 diluted in PBS for 5 min, and washed and blocked with 0.5% normal goat
serum in PBS (PBS-NGS). Coverslips were then incubated in mouse monoclonal antip53 DO-1 (Calbiochem, Billerica, MA, USA), rat monoclonal anti-VDR 9A7 (SigmaAldrich, St. Louis, MO, USA) and rabbit polyclonal anti-p63 H129 (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) primary antibodies for 1 hr at room temperature.
Excess primary antibody was removed with three consecutive 5 min washes in PBS-NGS
followed by incubation with AlexaFluor goat anti-rabbit 488 and goat anti-rat 568
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antibodies at a dilution of 1:500 for 1 hr at room temperature. Excess secondary was
removed with three consecutive 5 min washes in PBS-NGS and one wash in PBS prior to
mounting with Vecta-Shield plus DAPI Mounting Media (Vector Laboratories,
Burlingame, CA, USA). Cells were visualized and imaged using a Leica CTR 6000
Microscope (Leica Microsystems, Wetzlar, Germany) and ImagePro 6.2 software (Media
Cybernetics, Bethesda, MD). Mean fluorescent intensity was determined with the
ImagePro 6.2 software after normalizing to background fluorescence. At least 100 cells
were measured for VDR and p63 staining intensity per condition for each experiment
with n = 3 independent biological replicates. Student’s t-tests were used to determine
significant differences relative to vehicle controls.
E. Immunoprecipitation
Whole cell lysates were prepared by lysing cells in NP-40 lysis buffer (25 mM
Tris, pH 8.0, 150 mM NaCl, 0.5 mM EDTA, 0.5 mM EGTA, 1% Nonidet P-40, 1 mM
sodium orthovanadate, 1mM NaF, 1 mM NaPP and 1 mM DTT) supplemented with 10%
protease inhibitor cocktail (Sigma, St. Louis, MO). Cell lysates were subjected to four
10-second pulses on a 60 Sonic Dismembranator (Thermo Fisher Scientific Inc.,
Fremont, CA, USA). Cell debris was removed by centrifuging the samples at 14,000 g for
10 minutes. Total protein concentrations in the supernatant were determined by BCA
assay (Thermo Fisher Scientific Inc., Fremont, CA, USA) and equivalent protein
concentrations ranging for 500 μg to 1 mg were used for Immunoprecipitation (IP).
Immunoprecipitates were pre-cleared with 10 μL of protein A agarose beads (Santa Cruz
Biotechnology, Santa Cruz, CA, USA), followed by a 3-hour incubation with 30 μL
protein A agarose beads and either monoclonal anti-myc-tag antibody (9B11) (Cell
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Signaling Technology, Danvers, MA, USA) as a isotype control IP, or monoclonal antip53 antibody (DO-1) (EMD Millipore, Billerica, MA, USA). Following incubation bead
complexes were wash thrice with 0.5% Tween-20 in PBS. Protein complex formation
was detected by immunoblot analysis as described below.
F. Immunoblot analysis
Whole cell lysates were prepared by lysing the cells in phosphatase inhibitor
containing buffer (50mM Tris-HCl pH 8, 120 mM NaCl, 5mM NaPPi, 10mM NaF, 30
mM paranitrophenylphosphate, 1mM benzamidine, 0.1% NP-40, 1% Triton X-100 and
0.2 PMSF, 100nM sodium orthovanadate) supplemented with protease inhibitor cocktail
(Sigma, St. Louis, MO). Total protein concentrations were determined by BCA assay
(Thermo Fisher Scientific Inc., Fremont, CA, USA). Equivalent concentration of proteins
were resolved on 10% SDS-PAGE and transferred to polyvinylidene difluoride (PVDF)
membranes. Proteins were detected using the following antibodies: mouse monoclonal
anti-p53 DO-1 (EMD Millipore, Billerica, MA, USA), rabbit polyclonal anti-phosphoAkt (Ser473), rabbit polyclonal anti-Akt, rabbit polyclonal anti-p38, rabbit polyclonal
anti-phospho-p38 (Thr180/Tyr182), rabbit monoclonal anti-phospho-MAPKAPK-2
(Thr222), rabbit polyclonal anti-MAPKAPK-2 (Cell Signaling Technology, Danvers,
MA, USA), mouse monoclonal anti-VDR D-6, mouse monoclonal anti-pan-p63 4A4 and
mouse monoclonal anti-β-actin and rabbit polyclonal anti-GFP (FL) antibodies (Santa
Cruz Biotechnology, Santa Cruz, CA, USA). Anti-GFP (FL) antibody was obtained from
the laboratory of Dr. Michael Leffak at Wright State University, Dayton, OH.
Appropriate horseradish peroxidase-conjugated secondary antibodies in a dilution range
from 1:2500 to 1:5000 (Promega, Madison, WI, USA) were used for chemiluminescence
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detection with Western Lightning Plus chemiluminescent kit (Perkin Elmer, Waltham,
MA, USA). Band intensities were normalized to -actin, and fold changes in protein
expression were calculated relative to vehicle or non-silencing controls (NSC).
G. Cell growth assays
Cells were seeded at 5000 cells per well in a 96-well flat bottom culture dish, and
treated with 1 nM, 10 nM or 100 nM VD3 24 hour later. Proliferation was assessed using
Promega CellTiter 96 AQueous One Solution Cell Proliferation Assay (MTS) (Thermo
Fisher Scientific Inc., Fremont, CA, USA) at various time points post-treatment
according to established methods (Leonard et al., 2011). Student’s t-tests were used to
determine significant changes in cell proliferation relative to vehicle controls from three
independent biological replicates. Cell viability was also measured by trypan blue
exclusion and carried out in triplicate per condition per day post VD3 treatment.
H. Tissue Immunofluorescence Staining
Formalin fixed, paraffin-embedded human skin sections were stained for p63, and
VDR as previously described (Kommagani et al., 2009; Leonard et al., 2011) with one
modification. Briefly, the humans tissue were co-stained for p63 and VDR with two
different antigen retrieval processes, a heat base antigen retrieval method was used for
p63 followed by (Kommagani et al., 2009; Leonard et al., 2011) an acid antigen retrieval
processes for VDR and finally neutralization with 0.1 M Borate Buffer pH 8.5 (Hill et al.,
2014). Human tissue samples consisted of normal skin (N=49), precursor to SCC (N=59)
which included actinic keratosis (AK) N=22, acantholytic actinic keratosis (AA) N=6,
acantholytic and hyperplastic actinic keratosis (AKAH) N=10, hyperplastic actinic
keratosis (HA) N=15, squam in situ N=4 and bowenoid actinic keratosis (BA) N=2, SCC
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(N=53) which included superficial squamous cell carcinoma (SSCC) N=13, squamous
cell carcinoma with perineural invasion, squamous cell carcinoma (SCC) N=3, BCC
(N=54) which included infiltrative basal cell carcinoma (IBCC) N=4, nodular basal cell
carcinoma (NBCC) N=29, nodular and infiltrative basal cell carcinoma (NIBCC) N=6
and superficial basal cell carcinoma (SBCC) N=15. Tissues were imaged using a Leica
CTR 6000 Microscope (Leica Microsystems, Wetzlar, Germany). Three pictures per
tissue at sites that represents a constant staining for the tissue were taken on the Leica
CTR 6000 Microscope. Three measurements, all the same size, of the mean fluorescence
intensity were taken of the epidermal tissue or cancerous tissues for each picture.
Average mean fluorescence intensity was calculated following normalization to
background by using the ImagePro 6.2 software.
I. Statistical analysis for stained tissue
Adjusted mean MFI and standard error of mean (SEM) levels of p63 and VDR from
normal skin samples, Basal cell carcinoma samples, Squamous cell carcinoma samples,
and precursor to Squamous cell carcinoma samples were plotted. Repeated measures
Analysis of Variance (ANOVA) tests were conducted to account for the correlation
between repeated measurements (9 measurements per sample). A comparison of several
covariance structures was performed to find the best covariance structure as determined
using the Akaike Information Criterion (AIC) (Akaike, 1974).

Post-hoc multiple

comparison procedures using Dunnett’s test were performed to compare between mean
MFI values of p63 or VDR between control samples (i.e., normal skin samples) and all
other carcinoma samples (Dunnett, 1955, 1980).

PROC MIXED procedure
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(SAS/STAT®, Ver 9.3, SAS Institute Inc., Cary, NC) was used for analyses. Experiment
wise error rates under 0.05 were considered statistically significant.
J. Quantitative Reverse transcription PCR for gene expression
Total RNA was extracted from human cells using the eZNA RNA isolation kit according
to the manufacturer protocol (Omega Bio-Tek, Norcross, GA, USA). Total RNA
extracted from the skin of VDR knockout mice and wild type littermates were provided
by Dr. Glendon Zinser (University of Cincinnati) in full accordance with the Institutional
Animal Care and Use Committee of the University of Cincinnati. A TaqMan reverse
transcription kit (Life Technologies, Carlsbad, CA USA) was used to synthesize cDNA
from 1g of total RNA. Quantitative real-time PCR analysis was performed as previously
described using an Assay on Demand (AOD) specific for the genes of interest and
normalized to endogenous GAPDH for human genes or to β-actin for murine genes of
interest (Life Technologies, Carlsbad City, CA, USA) (Pfaffl, 2001; Kommagani et al.,
2009). Human AODs used were GAPDH (4325792), VDR (Hs0017213_ml), p53
(Hs00153340_m1) and pan-p63 (Hs00978340_ml). Murine AODs used were pan p63
(Mm00495788_m1), VDR (Mm00437297_m1) and β-actin (Mm00607939_s1). Each
experiment had an n = 3 independent experiments. Student’s t-tests were used to
determine significant difference relative to controls.
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III. RESULTS
A. VDR is essential for basal expression of Np63
To determine if VDR increases Np63 expression in vitro, I used several
keratinocyte cell lines. HaCaT cells, the most commonly used spontaneously
immortalized keratinocyte cells, were used in all experiments (Boukamp et al., 1990;
Mueller et al., 2001). The HaCaT cell line closely resembles normal keratinocyte in
growth and differentiation patterns (Mueller et al., 2001). Furthermore, the cell line does
not contain any viral sequences that could introduce genomic instability, thus allowing
them to remain non-tumorigenic over numerous passages (Mueller et al., 2001). The
HaCaT cell line contains two mutant alleles of p53 (H179Y and R282W) that are a result
of UV irradiation and are thought to contribute to the spontaneous transformation
(Mueller et al., 2001; Yang, D. et al., 2007; Li, X. et al., 2012) (Figure 3). HaCaT II-4, a
HaCaT clone, was produced by the addition of H-Ras to the HaCaT genome (Boukamp et
al., 1990; Mueller et al., 2001) allowing the cells to become tumorigenic (Boukamp et
al., 1990; Mueller et al., 2001). The HaCaT II-4 cell line was used in the experiments
investigating the effect of VDR on Np63. The A431-EGFR cell line is a squamous
carcinoma cell line which overexpresses epidermal growth factor receptor (EGFR)
(Yamamoto et al., 1986). A431 cells express two different Gain-of-function mutant
alleles of p53 (R273H and R273C) (Somers et al., 1992; Mueller et al., 2001; Rantanen
et al., 2002; Yang, D. et al., 2007; Li, X. et al., 2012) (Figure 3). The A431 cell line was
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originally derived from the squamous cell carcinoma lesion of an 85 year old woman
(Thomasen et al., 2015). This cell line was used to validate the effects of VDR or VD3 on
Np63 expression seen in the keratinoycte cell lines thereby acting as a squamous cell
carcinoma model. Finally, to determine the effects of VDR on Np63 in cells with wild
type p53, I also used the neonatal human keratinocyte cell line (nHEK) isolated from the
foreskin of newborn infants (Rheinwald & Green, 1977).
Previous studies in our laboratory have shown that VDR is a direct target of
Np63. (Kommagani et al., 2006; Kommagani et al., 2009). Unfortunately, no studies
to date have examined whether VDR can up-regulate Np63. Since, both VDR and
p63 are important in skin development, it is likely that both might contribute to the onset
and progression of NMSC. Thus, it is imperative to understand the mechanism by which
both proteins regulate each other and elicit downstream effects in cancer. The VDR
ligand, VD3, enhances survival and proliferation in keratinocytes (Bollag et al., 1995;
Zhang, Y. et al., 2006; Zhang, X. & Zanello, 2008; Kovalenko et al., 2011), while
Np63 is plays a major role in maintaining the proliferative capacity of basal layer
keratinocytes (Mills et al., 1999). Since both Np63 and VDR/VD3 can increase
keratinocyte proliferation, I first examined if VDR mediates keratinocyte proliferation by
regulating Np63 expression. Previously, immunoblot analysis showed that Np63 is
the only detectable p63 isoform expressed in HaCaT and A431 cells (Kommagani et al.,
2006; Kommagani et al., 2009). To determine if VDR positively regulates the expression
of Np63, I silenced VDR (siVDR) in two keratinocyte cell lines (HaCaT and HaCaT
II-4) and examined Np63 expression at both the protein and transcript levels. To
ensure that any change in Np63 observed upon loss of VDR was not an artifact of
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transformation or dependent on the p53 status, I also silenced VDR in primary nHEK,
which express wild-type p53. HaCaT, HaCaT II-4 and primary keratinocytes cells
transfected with siRNA against VDR showed a significant reduction in VDR transcript
and protein levels (Figure 8A and 8B), thus confirming siRNA function. Knockdown of
VDR in HaCaT, HaCaT II-4 and primary keratinocytes led to a concomitant reduction in
Np63 transcript and protein expression (Figure 8). Furthermore, when examining the
effects of loss of VDR in the squamous cell carcinoma cell line A431, I observed a
similar reduction in Np63 protein level as seen in the transformed and primary
keratinocyte cell lines (Figure 9). To confirm that VDR positively regulates Np63
expression in vivo, total RNA extracts from the skin of VDR knockout (KO) mice and
wild type littermates were analyzed by RT-PCR. Complete ablation of VDR significantly
reduced the transcript levels of p63 in the skin of VDR KO mice compared to wild type
controls (Figure 8C). Taken together, this data demonstrates that VDR positively
regulates Np63 expression in vitro and in vivo. In silico analysis of Chip-Seq data
revealed three VDREs upstream of the p63 gene and one VDRE in the 3’ untranslated
region (UTR) of p63 (Tuoresmaki et al., 2014), suggesting that it is likely p63 is a direct
transcriptional target of VDR.
B. Np63 protein levels increased following treatment with low dose VD3.
VDR functions in a ligand-dependent and ligand-independent manner in epidermal
keratinocytes (Haussler et al., 2011; Haussler et al., 2012). The ligand for VDR, VD3, is
synthesized in the skin by a reaction that requires UVB energy to convert 7dehydrocolestoral to the biologically active form 1, 25-dihydroxyvitamin D3 called
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Figure 8: VDR is critical for basal expression of Np63. (A) HaCaT (left panel),
HaCaT II-4 (right panel) and (B) NHEK cells were transfected with non-silencing control
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(NSC) or siRNA specific for VDR. Changes in mRNA levels and protein expression of
p63 and VDR were measured by qRT-PCR (*=p values ≤ 0.05) and immunoblot
analyses, respectively. The fold-change in protein levels, relative to NSC transfected
cells, is listed above each band. (C) Total RNA extracted from skin of wild type or VDR
knockout (KO) mice was subjected to qRT-PCR to measure the change in VDR and p63
transcript levels. *=p values ≤ 0.05. (Hill et al., 2015).
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Figure 9: Loss of VDR reduced Np63 protein expression in A431 cells. A431 cells
were transfected with non-silencing control (NSC) or siRNA against VDR. The change in
p63 and VDR was measured by immunoblot analysis. The fold-change in protein levels,
relative to NSC transfected cells, is listed above each band. (Hill et al., 2015).
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calcitrol. UV radiation is also the most common cause of NMSC, and NMSCs frequently
overexpress Np63. Thus, it is important to determine if VD3 contributes to VDRmediated regulation of Np63 and what phenotypic changes occur due to alteration in
Np63 expression. Having demonstrated that VDR is important for maintaining basal
expression of Np63, I next wanted to determine whether VDR modulates Np63
expression in a ligand-dependent or -independent manner. First, I examined the effects of
increasing doses of VD3 on Np63 expression and observed a dose dependent increase
in Np63 levels up to 10 nM, while 50 nM and 100 nM VD3 showed a decline in
Np63 expression relative to cells treated with 10 nM VD3 (Figure 10). Furthermore,
VDR protein expression increased in a dose dependent manner following VD3 treatment
(Figure 10). Therefore, I utilized 10 nM and 100 nM VD3 in subsequent experiments to
evaluate any changes in Np63 expression induced by VD3 in HaCaT, HaCaT II-4 and
A431 cells. Furthermore, the 10 nM dose of VD3 is more in line with VD3 deficiency and
the 100 nM dose in similar to a dose that is consider cancer preventive (Cannell & Hollis,
2008; Ross et al., 2011) in humans. While treatment with low dose VD3 increased
Np63 protein levels in HaCaT, HaCaT II-4 and A431 cells (Figure 11 and Figure 12),
high doses of VD3 did not significantly affect Np63 protein levels relative to vehicle
controls at 24 hours post VD3 treatment (Figure 11). As shown in Figure 11 and
consistent with Figure 10, VDR levels increased in a dose dependent manner following
24 hours of VD3 treatment. To further confirm VD3 mediated increases in Np63, I
measured the changes in Np63 expression via immunofluorescence. Consistent with
immunoblot analysis, immunofluorescent staining of p63 and VDR in cells treated with
10 nM of VD3 clearly showed an increase in
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Figure 10: VD3-mediated increase in Np63 protein expression peaks at the 10 nM
dose of VD3. HaCaT cells were treated with vehicle, 1 nM VD3, 5 nM VD3 10 nM VD3,
50 nM VD3 or 100 nM VD3 for 24 hours then subjected to immunoblot analysis for
Np63, VDR and β-actin. The fold-change in protein levels, relative to vehicle treated
cells, is listed below each band. (Hill et al., 2015).

40

Figure 11: VD3 dosage differentially affects Np63. HaCaT (A) and HaCaT II-4 (B)
cells were treated with vehicle, 10 nM VD3 or 100 nM VD3 for 24 hours then subjected to
immunoblot analysis for Np63, VDR and β-actin. The fold-change in protein levels,
relative to vehicle treated cells, is listed above each band. (Hill et al., 2015).
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Figure 12: VD3 dosage differentially affects Np63 expression in A431 cells. A431
cells were treated with vehicle, 10 nM VD3 or 100 nM VD3 for 48 hours then subjected to
immunoblot analysis for Np63, VDR and β-actin. The fold-change in protein levels,
relative to vehicle treated cells, is listed above each band. (Hill et al., 2015).
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Figure 13: Low dose VD3 increases Np63 expression. Top panel: HaCaT and
HaCaT II-4 were treated with vehicle, 10 nM VD3 or 100 nM VD3 overnight followed by
detection of ΔNp63α and VDR by immunofluorescence. Bottom panel: average mean
intensity of immunofluorescence staining for ΔNp63α and VDR in HaCaT and HaCaT II4. Error bars represent standard error of the mean. *=p values ≤ 0.05 compared to
vehicle control cells. Each sample consists of a 100 counted cells per experiment. (Hill et
al., 2015).
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Np63 expression compared to 100 nM of VD3 or vehicle treated cells (Figure 13).
These results establish that only low doses of VD3 lead to increased Np63 protein
levels. Therefore, this data indicates that changes in VD3 levels following UV radiation
could potentially be one factor that leads to increased Np63 expression in NMSC.
C. VD3 increases Np63 transcript level
Classical VD3 signaling involves the transcription of VDR target genes induced
by binding of VD3 (Deeb et al., 2007; Haussler et al., 2011). Thus far, I have shown that
VDR positively regulates Np63 and that low dose VD3 increases Np63 protein
expression. In order to understand the mechanism behind VD3-mediated regulation of
Np63, I next examined whether VD3 treatment affects Np63 transcription. To test
whether VD3 increases Np63 transcript, I examined the transcripts levels of p63, VDR
and CYP24A in HaCaT (Figure 14A) and HaCaT II-4 (Figure 14B) cells following
treatment with 10 nM or 100 nM VD3 for 24 hours. As a positive control, I measured
transcript levels of a known target of VD3, CYP24A. Both concentrations of VD3 led to a
modest but significant increase in p63 transcript levels when compared to vehicle treated
controls. VD3 did not significantly affect VDR transcript levels at 100 nM VD3 in HaCaT
and at both doses tested in HaCaT II-4. As expected, there was a dose dependent
increase in the CYP24A transcript levels following VD3 treatment. Taken together, both
100 nM and 10 nM doses of VD3 modestly increased p63 transcript levels, indicating that
VD3 can potentially increase Np63 transcript levels. Unfortunately, I did not observe a
significant increase in Np63 protein expression with 100 nM VD3, which may point to
alternative mechanisms by which low dose VD3 increases Np63 such as kinase
activation leading to increased Np63 protein stabilization.
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Figure 14: VD3 increases Np63 transcript levels. (A) HaCaT and (B) HaCaT II-4
cells were treated with vehicle, 10 nM VD3 or 100 nM VD3 for 24 hours. Transcript
levels of p63 (top panel), VDR (middle panel) and CYP24A (bottom panel) were
analyzed by TaqMan based qRT-PCR (*=p values ≤ 0.05). (Hill et al., 2015).
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D. VD3 mediated induction of Np63 occurs via p38 and Akt activation.
Since the effects of VD3 on the Np63 transcript level did not mimic the
observed changes in protein expression, I decided to examine alternative mechanism by
which low dose VD3 could lead to increased Np63 protein levels. Previous studies
have shown that VD3 treatment increases Akt activation, particularly with a 10 nM dose
of VD3 (Zhang, Y. et al., 2006; Zhang, X. & Zanello, 2008). Furthermore, low doses of
VD3 are not considered to be cancer preventive, but could potentially contribute to cancer
onset and progression (Garland et al., 2009; Ness et al., 2015). The Akt pathway,
commonly elevated in cancer, has been shown to increase Np63 protein expression
(Ogawa et al., 2008). Thus, I investigated whether activated Akt was required for the
increased Np63 protein levels observed upon low dose VD3 treatment. I measured
Akt activation after treatment with VD3 using an antibody directed against
phosphorylated serine 473 of Akt (pAkt), indicative of fully activated Akt. I observed
that Akt activation by low dose VD3 occurred within five minutes. This activation of Akt
preceded the increase in Np63 protein levels, which occurred within 2 hours (Figure
15). To show that increased Np63 levels and cell growth observed upon low dose VD3
treatment is as a result of activated Akt, I next examined the effect of VD3 on Np63
levels following inhibition of Akt activity with a small molecule allosteric Akt-specific
inhibitor, MK2206. MK2206 prevents Akt binding PIP3 via its pleckstrin homology
domain preventing Akt phosphorylation at T308 and S473 and thereby Akt activation
(Yap et al., 2011). Inhibition of Akt activity reduced Np63 levels in all conditions
(Figure 16). However, low dose VD3 treatment in conjunction with MK2206 still
exhibited
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Figure 15: VD3-mediated increased Np63 levels follows Akt activation. HaCaT
cells were treated with 10 nM or 100 nM VD3 and harvested at different time points as
indicated. Whole cell lysates were subjected to immunoblot analysis for p63, pAkt, Akt
and β-actin. (Hill et al., 2015).
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Figure 16: VD3 up-regulates Np63 levels partly through Akt activation. HaCaT
cells were pretreated with 10 M of the Akt inhibitor MK2206 or DMSO control for 1
hour followed by treatment with either vehicle, 10 nM VD3 or 100 nM VD3 in
combination with DMSO or MK2206 for 24 hours. Whole cell lysates were subjected to
immunoblot analysis for the indicated proteins. The fold-change in protein levels for
Np63, relative to DMSO/vehicle control treated cells is listed below each band. (Hill
et al., 2015).
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slightly higher levels Np63 when compared to cells treated with MK2206 and vehicle
(Figure 16). Together this data indicates that Akt only partially regulates Np63 protein
expression in response to VD3.
Since Akt only partially regulates Np63 following VD3 treatment, I next
examined the role of p38 Mitogen activated protein kinase (MAPK) signaling pathway in
VD3 mediated increases in Np63 levels. In addition to VD3 treatment, a variety of
other stimuli such as stress, growth factors and cytokines have been shown to activate
p38 MAPK (Buitrago, C. G. et al., 2006; Buitrago, C. & Boland, 2010). Activated p38
MAPK was shown to increase ΔNp63α levels and cell proliferation in limbal epithelial
cells (Cheng et al., 2009). Furthermore, p38 MAPK down-regulates cell cycle
progression and proliferation through the phosphorylation of downstream transcription
factors, such as p53, or kinases such as MAPK-activated protein kinase 2 (MAPKAPK-2
or MK2). MAPKAPK-2 is a well-known p38 MAPK target and is routinely used to
confirm p38 MAPK activation in response to many stimuli. Originally, p38 MAPK was
thought to inhibit proliferation, but studies in muscle cells support the idea that p38
MAPK can also promote cell proliferation (Zarubin & Han, 2005; Buitrago, C. G. et al.,
2006; Buitrago, C. & Boland, 2010; Cuadrado & Nebreda, 2010). This suggests that that
activation of p38 MAPK following VD3 treatment could increase Np63 protein levels,
thereby increasing keratinocyte proliferation. Therefore, I wanted to determine if p38
activation upon VD3 treatment was required to increase Np63 protein levels. To assess
p38 MAPK activation by VD3 in HaCaT cells following treatment with 10 nM and 100
nM of VD3, I monitored phosphorylation of p38 MAPK and its downstream target
MAPKAPK-2 at various time points post-treatment. VD3 induced the phosphorylation of
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Figure 17: VD3 increases p38 activation prior to increasing Np63 levels. HaCaT
cells were treated with 10 nM or 100 nM VD3 and harvested at different time points as
indicated. Whole cell lysates were subjected to immunoblot analysis for p-p38, p63,
pMAPKAPK-2, p38 and β-actin. (Hill et al., 2015).
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both p38 MAPK and MAPKAPK-2 within five minutes of VD3 treatment and this
activation persisted longer following treatment with 10 nM VD3 when compared to 100
nM VD3 treatment (Figure 17). Consistent with Figure 15, I observed an increase in
Np63 protein levels following kinase activation in response to treatment with 10 nM
VD3 (Figure 17). To confirm that VD3 increased Np63 protein levels via p38 MAPK
activation, I next examined whether pre-treatment with the p38 MAPK inhibitors
SB202190 or BIRB-796 prior to VD3 treatment would lead to a decrease in Np63
protein levels. The p38α and p38β inhibitor, SB202190, inhibits the active form of p38
MAPK by competing with ATP for the ATP binding pocket (Young, P. R. et al., 1997;
Frantz et al., 1998). The pan-p38 inhibitor, BIRB-796, forms a hydrogen bond between
the morpholine oxygen and the ATP binding domain (Pargellis et al., 2002). Use of the
SB202190 p38 MAPK inhibitor lead to a reduction in the activation of the p38 MAPK
downstream target MAPKAPK-2 measured by a decrease in the upper band indicative of
phosphorylation (Figure 18). Furthermore, inhibition of p38 with BIRB-796 led to a
reduction in p-p38 MAPK levels and subsequently a reduction in the activation of
MAPKAPK-2 (Figure 19). Inhibition of p38 activity by both SB202190 and BIRB-796
led to a reduction in the Np63 protein levels as shown in Figure 18 and Figure 19,
respectively. Furthermore, low dose VD3 was unable to rescue ΔNp63α levels when p38
MAPK activation was inhibited (Figure 18 and Figure 19), indicating that increased
Np63 levels in response to low doses of VD3 occur via p38 MAPK activation.
E. Effects of VD3 treatment on cell proliferation correlates with Np63
protein levels.

51

Figure 18: Inhibition of p38 activation with the p38α/β inhibitor SB202190 reduced
VD3-mediated increase in Np63. HaCaT cells were pretreated with 15 M
SB202190 or DMSO control for 1 hour followed by treatment with either vehicle, 10 nM
VD3 or 100 nM VD3 in combination with DMSO or SB202190 for 24 hours. Whole cell
lysates were subjected to immunoblot analysis for the indicated proteins. The fold-change
in protein levels for Np63, relative to DMSO-vehicle treated cells is listed below each
band. Arrow indicate the location of pMAPKAPK-2. (Hill et al., 2015).
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Figure 19: Inhibition of p38 activation with the pan-p38 inhibitor BIRB-796
reduced VD3-mediated increase in Np63. HaCaT cells were pretreated with 1 M
BIRB-796 or DMSO control for 2 hours followed by treatment with either vehicle, 10
nM VD3 or 100 nM VD3 in combination with DMSO or BIRB-796 for 24 hours. Whole
cell lysates were subjected to immunoblot analysis for the indicated proteins. The foldchange in protein levels for Np63, relative to DMSO-vehicle treated cells is listed
below each band. (Hill et al., 2015).
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Previous studies have shown a correlation between increased Np63 expression
and cell proliferation in squamous cell carcinomas (Reis-Filho et al., 2002; Sniezek et al.,
2004; Lo Muzio et al., 2005). Furthermore, Np63 is expressed predominantly in the
proliferative basal level of epithelial tissues. Since low dose VD3 increased Np63
levels (Figures 10-14), I examined whether low dose VD3 treatment also led to increased
keratinocyte proliferation, as Np63 has been showed to increase proliferation (Danilov
et al., 2011). To assess this, I monitored cell proliferation by MTS assay and trypan blue
exclusion at various time points following treatment of cells with VD3. As seen in Figure
20, 10 nM VD3 significantly increased proliferation in both HaCaT and HaCaT II-4 cells,
while 100 nM VD3 reduced cell proliferation when compared to vehicle treated controls.
I further confirmed dose effect of VD3 on increased cell proliferation by counting trypan
blue stained HaCaT and HaCaT II-4 cells treated with 1, 10, or 100 nM doses of VD3 as
shown in Figure 21A. Consistent with results obtained using MTS assay (Figure 20 and
Figure 21A), live cell number by trypan blue exclusion confirmed an increased cell
number with 1 nM and 10nM of VD3 while 100 nM of VD3 did not significantly alter cell
number when compared to vehicle treated cells (Figure 21B). Together our results
demonstrate that VD3 affects cell proliferation in a dose-dependent manner and
correlating with the effects of VD3 on Np63 levels (Figure 11).
F. VDR and p63 are both play a major role in VD3-mediated cell proliferation
VD3 was previously shown to function independently of its receptor, VDR (Wali
et al., 2003) thus bringing to the light the possibility that VDR may not be necessary for
VD3 mediated increase in keratinocyte proliferation which correlates with VD3 mediated
increase Np63 protein levels. Therefore, I wanted to determine if VD3 mediated
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Figure 20: VD3 dosage differentially affects cell proliferation. HaCaT (A) and HaCaT
II-4 (B) cells were treated with vehicle, 10 nM VD3 or 100 nM VD3 for 8, 24 and 48
hours and cell proliferation was measured by MTS cell titer assay. The Y-axis indicates
fold change compared to vehicle treated cells. Error bars represent standard deviation
from the mean. *=p values ≤ 0.05 compared to vehicle control cells at 8 hours. (Hill et
al., 2015).
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Figure 21: Low dose VD3 increases keratinocyte proliferation. (A) HaCaT and HaCaT
II-4 cells were treated with vehicle, 1 nM VD3, 10 nM VD3, or 100 nM VD3 for 8, 24, 48
and 72 hours then cell proliferation was measured post each VD3 treatment by MTS
assay. (B) HaCaT and HaCaT II-4 cells were treated with vehicle, 1 nM VD3, 10 nM
VD3, or 100 nM VD3 for 24, 48 and 72 hours followed by cell proliferation measurement
by trypan blue cell exclusion. Error bars represent standard deviation from the mean.
(Hill et al., 2015).
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effects on keratinocyte proliferation are dependent on VDR expression. To this end, I
examined the effects of VDR knockdown on cell proliferation following VD3 treatment.
HaCaT and HaCaT II-4 cells were transfected with non-silencing control siRNA or VDR
specific siRNA followed by treatment with VD3. As expected, low dose VD3 increased
HaCaT and HaCaT II-4 cell proliferation when compared to vehicle control treated cells
that were transfected with non-silencing control siRNA (Figure 22). Knockdown of VDR
dramatically reduced cell proliferation in both HaCaT and HaCaT II-4 cells, regardless of
VD3 dose when compared to control siRNA transfected cells (Figure 22A and 22B top
panel). Immunoblot analyses of cells treated with VD3 following knockdown of VDR
confirmed VDR loss following silencing with siRNA against VDR (Figure 22A and 22B
bottom panel). Furthermore, loss of VDR in VD3 treated cells lead to a reduction in the
basal Np63 levels as well as significantly reduced 10 nM VD3 mediated induction of
Np63 protein when compared to control cells (Figure 22A and 22B bottom panel).
Taken together this data shows that VDR plays an important role VD3 mediated increase
in Np63 and keratinocyte proliferation, indicating that the regulation of Np63 and
keratinocyte proliferation is a VDR ligand dependent function. Since Np63 contributes
to increased proliferation and its expression is dependent on VDR, I next wanted to
confirm if the decreased Np63 expression observed after knockdown of VDR was
responsible for the concomitant reduction in proliferation. Therefore, p63 was silenced
with siRNA specific to p63 prior to VD3 treatment of HaCaT and HaCaT II-4 cells. As
expected, low dose VD3 led to a significant increase in keratinocyte proliferation when
compared to vehicle or 100 nM VD3 treated cells transfected with non-silencing control
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Figure 22: VDR is important for VD3-mediated cell proliferation. HaCaT (A) and
HaCaT II-4 (B) cells were transfected with non-silencing control (NSC) or siVDR
followed by treatment with vehicle control, 10 nM or 100 nM VD3 for 8, 24 and 48 hours
as indicated. Cell proliferation was measured by MTS cell titer assay. Y-axis represents
fold change compared to NSC transfected vehicle treated cells. Error bars represent
standard deviation from the mean. *=p values ≤ 0.05 compared to NSC vehicle control
cells at 8 hours. Confirmation of silencing was measured by Western blot following VD3
treatment (lower panels). (Hill et al., 2015).
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siRNA (Figure 23A and 23B top panel). Silencing p63 dramatically reduced cell
proliferation in cells treated with vehicle, 10 nM or 100 nM of VD3 compared to cells
transfected with control siRNA and VD3. This shows that Np63 is important for VD3
mediated increases in keratinocyte cell proliferation (Figure 23A and 23B top panel).
Previously, our laboratory showed that Np63 positively regulates VDR transcription
and protein expression. Here, I wanted to determine the effect of Np63 knockdown on
VD3-mediated increase in VDR. Immunoblot analysis for VDR following p63
knockdown and in HaCaT and HaCaT II-4 cells treated with VD3 demonstrated a
reduction in the VD3-mediated increases in VDR protein levels (Figure 23A and 23B
bottom panel). To confirm that the change in cell proliferation was not an artifact of the
MTS assay, I also measured the change in cell viability following VD3 treatment of
HaCaT and HaCaT II-4 that were transfected with siRNA against p63 or VDR by trypan
blue exclusion. Consistent with MTS assay, cells transfected with control siRNA showed
a dramatic increase in cell proliferation in response to low dose VD3 treatment (Figure
24). As shown in Figure 24, I observed that loss of p63 or VDR led to a reduction in
VD3-mediated increase in keratinocyte proliferation by trypan blue cell counting further
confirming that both p63 and VDR are important for VD3-mediated increase in cell
proliferation.
G. VD3 mediated increase keratinocyte proliferation involves p38 and Akt
activation.
Akt activation was partly involved in VD3 mediated increase in Np63
expression. Therefore, I decided to examine the combined effects of loss of VDR
expression and inhibition of Akt on keratinocyte proliferation following VD3 treatment.
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Figure 23: Np63 is important for VD3-mediated cell proliferation. HaCaT and
HaCaT II-4 cells were transfected with non-silencing control (NSC) or sip63 followed by
treatment with vehicle control, 10 nM or 100 nM VD3 for 8, 24 and 48 hours as indicated.
Cell proliferation was measured by MTS cell titer assay. Y-axis represents fold change
compared to NSC transfected vehicle treated cells. Error bars represent standard
deviation from the mean. *=p values ≤ 0.05 compared to NSC vehicle control cells at 8
hours.

Confirmation of silencing was measured by Western blot following VD3

treatment (lower panels). (Hill et al., 2015).
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Figure 24: Confirmation that VDR and Np63 play a role in VD3-mediated
increase in cell proliferation. HaCaT (A) and HaCaT II-4 (B) cells were transfected
with siRNA against p63 or VDR followed by treatment with vehicle control or VD3 at 10
nM or 100 nM for 24 and 48 hours. Cell viability was measured by trypan blue cell
exclusion. Error bars represent standard deviation from the mean. *=p values ≤ 0.05
compared to NSC vehicle control cells at 24 hours. (Hill et al., 2015).
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To this end, I measured changes in proliferation in HaCaT cells pre-treated with MK2206
(inhibitor of Akt activation) for 1 hour in presence or absence of VDR followed by VD3
treatment in the presence or absence of MK2206 for 24 hours. Loss of VDR alone or
inhibition of Akt alone reduced HaCaT proliferation to similar levels regardless of VD3
dose (Figure 25). Interestingly, loss of VDR combined with Akt inhibition led to a further
reduction in cell proliferation. This data is consistent with the effect of loss of Akt
activation on Np63 protein and suggests that increased keratinocyte proliferation
following low dose VD3 treatment is likely only partially occurring via VD3 mediated
activation of Akt.
Having shown that p38 MAPK is involved in VD3-mediated increase in Np63,
I next wanted to show a correlation between the effects of p38 MAPK on Np63 and
keratinocyte proliferation following VD3 treatment in the absence or presence of VDR.
Therefore, I studied the effects of SB202190 (p38 MAPK inhibitor) pre-treatment on cell
proliferation in presence or absence of VDR following VD3 treatment in HaCaT cells. As
expected in cells transfected with non-silencing control siRNA, there was an increase in
HaCaT proliferation following low dose VD3 treatment compared to control cells.
Inhibition of p38 MAPK with SB202190 led to a reduction in cell proliferation in cells
treated with 10 nM VD3 compared to vehicle controls and high dose VD3-treated cells
(Figure 26). Loss of VDR alone or in combination with p38 MAPK inhibition with
SB202190 reduced keratinocyte proliferation to similar levels regardless of VD3
treatment (Figure 26). This data indicates that p38 MAPK plays a role in VD3-mediated
increases in keratinocyte proliferation in the presence of VDR.
To further confirm p38 MAPK is involved in VD3-mediated increase in Np63
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Figure 25: VD3 up-regulates keratinocyte proliferation in the presence of VDR
partly through Akt activation. HaCaT cells were transfected with non-silencing control
(NSC) or siRNA against VDR. Cells were incubated for 1 hour in media containing 10
M Akt inhibitor MK2206 or DMSO control prior to treatment with the indicated doses
of VD3 or vehicle for 24 hours and MK2206 or DMSO. Cell proliferation was measured
24 hours post VD3 treatment by MTS assay. Error bars represent standard deviation from
the mean. *=p values ≤ 0.05 compared to NSC/DMSO/vehicle control cells. (Hill et al.,
2015).
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Figure 26: Loss of VDR and inhibition of p38 activation with the p38α/β inhibitor
SB202190 further reduced VD3-mediated increase in keratinocyte proliferation.
HaCaT cells were transfected with non-silencing control (NSC) or siRNA against VDR.
Cells were pretreated with 15 M SB202190 or DMSO control for 1 hour prior to
replacing media with fresh SB202190 and either vehicle, 10 nM VD3 or 100 nM VD3 for
24 hours. Cell proliferation was measured 24 hours post VD3 treatment by MTS assay.
Error bars represent standard deviation from the mean. *=p values ≤ 0.05 compared to
NSC/DMSO/vehicle control cells. (Hill et al., 2015).
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and thereby keratinocyte proliferation; I examined the effects of a second p38 MAPK
inhibitor (BIRB-796) on keratinocyte proliferation. To this end, I measured changes in
proliferation via MTS assay following the inhibition of p38 activation with BRIB-796 in
HaCaT cells in the presence or absence of VDR knockdown that were treated with
vehicle, 10 nM or 100 nM VD3. As expected, low dose VD3 increased keratinocyte
proliferation in cells transfected with non-silencing control siRNA that were treated with
VD3 (Figure 27). Consistent with the SB202190 p38 MAPK inhibitor, inhibition of p38
MAPK with BRIB-796 led to a reduction in cell proliferation of cells treated with 10 nM
VD3 compared to controls treated with vehicle or high dose VD3 (Figure 27). Inhibition
of p38 MAPK with BRIB-796 alone or in combination with loss of VDR alone reduced
keratinocyte proliferation to similar levels regardless of VD3 treatment (Figure 27).
Taken together, these data indicate that p38 MAPK in the presence of VDR is important
for low dose VD3-mediated increases in ΔNp63α protein levels, which correlates with
VD3-mediated effects on keratinocyte proliferation.
H. Np63 rescues VD3-mediated increase in proliferation following loss of VDR.
The data presented thus far shows a correlation between VD3-mediated effects on
ΔNp63α expression and keratinocyte proliferation in presence of VDR. Next, I wanted to
confirm that increased cell proliferation following low dose VD3 treatment was dependent
on VDR/VD3 mediated regulation of Np63 expression. Therefore, I generated HaCaT
stable cell lines expressing Np63 (HaCaT-Np63α) or eGFP (HaCaT-eGFP), the latter
used as a control. Stable expression of Np63 and GFP by western blot analysis,
showed that HaCaT-Np63 cells expressed increased levels of Np63 relative to
HaCaT-eGFP controls (Figure 28A). Furthermore, only the HaCaT-eGFP cells expressed
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Figure 27: Loss of VDR and inhibition of p38 activation with the pan-p38 inhibitor
BIRB-796 further reduced VD3-mediated increase in keratinocyte proliferation.
HaCaT cells were transfected with non-silencing control (NSC) or siRNA against VDR.
Cells were pretreated with 1 M BIRB-796 or DMSO control for 2 hours prior to
replacing media with fresh BIRB-796 or DMSO and either vehicle, 10 nM VD3 or 100
nM VD3 for 24 hours. Cell proliferation was measured 24 hours post VD3 treatment by
MTS assay. Error bars represent standard deviation from the mean. *=p values ≤ 0.05
compared to NSC/DMSO/vehicle control cells. (Hill et al., 2015).
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GFP protein (Figure 28A). Following confirmation of GFP and Np63 overexpression,
HaCaT-eGFP and HaCaT-Np63 were transfected with siRNA against VDR or nonsilencing control (NSC) siRNA followed by treatment with vehicle control, 10 nM or 100
nM VD3. At 24 hours post-VD3 treatment, cell viability was assessed by trypan blue
exclusion to quantify changes in proliferation. As shown in Figure 28B, low dose 10 nM
VD3 led to an increased cell number in both HaCaT-eGFP and HaCaT-Np63 cells
transfected with NSC compared to vehicle or 100 nM VD3 treated cells. Consistent with
data presented earlier (Figure 22), loss of VDR led to a reduction in HaCaT-eGFP cell
number regardless of VD3 dose (Figure 28B). Importantly, Np63 rescued the effects of
VDR knockdown in HaCaT-Np63 cells pre-treated with 10 nM VD3 (Figure 28B).
Taken together, our results confirm that increased keratinocyte proliferation following
treatment with low dose VD3 is dependent on VDR-mediated regulation of Np63
expression.
I. VDR and p63 expression are increased in non-melanoma skin cancer.
Np63 increases keratinocyte proliferation and has been shown to play a role in
maintaining the proliferative capacity of basal keratinocytes in vivo (Koster et al., 2004;
Carroll et al., 2006; Leonard et al., 2011; Romano & Sinha, 2011; Jeng-Yuan Yao, 2012;
Orzol et al., 2012).

Previous work from our laboratory has shown that ΔNp63α

positively regulates VDR. In this study, I have shown that VDR positively regulates
ΔNp63α expression. Since VDR up-regulates ΔNp63α and ΔNp63α is overexpressed in a
number of non-melanoma skin cancers (NMSC), I wanted to show that there is a
correlation between increased ΔNp63α levels, VDR levels in NMSC. Therefore, I
examined the expression levels of p63 and VDR in paraffin embedded skin
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Figure 28: Np63 rescues reduction in VD3-mediated cell proliferation following
loss of VDR. A) The expression of eGFP and Np63 were confirmed in HaCaT-eGFP
and HaCaT-Np63 stable cells via immunoblot analysis. B) HaCaT-eGFP and HaCaTNp63 stable pools were transfected with non-silencing control (NSC) or siVDR
followed by treatment with vehicle control, 10 nM or 100 nM VD3 for 24 hours. Cell
viability was measured following VD3 treatment by trypan blue cell exclusion. Error bars
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represent standard deviation from the mean. *=p values ≤ 0.05 compared to vehicle
control EGFP expressing HaCaT cells. #=p values ≤ 0.05 compared to 10 nM EGFP
expressing HaCaT cells. (Hill et al., 2015).
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samples from individuals with normal skin (N=49) and patients with the precursors to
SCC (N=59), squamous cell carcinoma (SCC) (N=53) and basal cell carcinomas (BCC)
(N=54) by immunofluorescence to determine if there is a correlation between p63 and
VDR expression levels. I observed higher levels of both p63 and VDR in BCC followed
by SCC and the precursors to SCC when compared to normal non-cancerous skin as
shown in representative images (Figure 29). Following quantitation I showed that the
levels of both p63 and VDR were significantly highest in BCC followed by SCC and
precursors to SCC (Figure 30). Furthermore, linear regression analysis shows that
increased p63 expression correlates with an increase in VDR expression in these samples
(Figure 31), indicating that there is a correlation between increased p63 and VDR levels
in NMSC.
In order to further understand the relationship between p63 and VDR in nonmelanoma skin cancers, I re-analyzed the expression of p63 and VDR levels based on the
different sub-types of precursors to SCC, SCC and BCC. As shown in Figure 33, mean
fluorescent intensity measurements showed increased expression of p63 in three of the
six precursors to invasive SCC; Actinic Keratosis Acantholytic Hyperplastic,
Hyperplastic Actinic Keratosis and Squamous cell carcinoma in situ, when compared to
normal skin (Figure 32 and Figure 33). Similar to p63, VDR also showed increased
expression in three of the six subtypes; Actinic Keratosis, Hyperplastic Actinic Keratosis
and Squamous cell carcinoma, but only Hyperplastic Actinic Keratosis and Squamous
cell carcinoma displayed significant increases in both VDR and p63 expression (Figure
32 and Figure 33). Moreover, examination of the expression levels of p63 and VDR in
three SCC subtypes demonstrated a statistically significant increase in both p63 and VDR
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Figure 29: Representative pictures of VDR and p63 increased expression in nonmelanoma skin cancer. Panels show representative images taken at a 20x magnification
of normal skin, precursors to squamous cell carcinoma, squamous cell carcinoma (SCC)
and basal cell carcinoma (BCC) from formalin fixed, paraffin-embedded human skin
stained for p63 and VDR (scale bar = 20 μm). (Hill et al., 2015).
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Figure 30: Increased VDR and p63 expression in non-melanoma skin cancer.
Quantitation of p63 (A) and VDR (B) levels from 49 normal skin samples, 59 precursors
to SCC samples, 53 SCC samples and 54 BCC samples are plotted. Y-axis represents the
mean fluorescent intensity, normalized to background, in arbitrary units. Error bars
represent standard error. *= p ≤ 0.05 compared to normal skin. (Hill et al., 2015).
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Figure 31: Increased p63 expression correlates with increased VDR expression in
NMSC. Linear regression plot of p63 and VDR average mean fluorescent intensity per
tissue of 49 normal skin samples, 59 precursors to SCC samples, 53 SCC samples and 54
BCC samples. Y-axis represents the mean fluorescent intensity of VDR, normalized to
background, in arbitrary units. X-axis represents the mean fluorescent intensity of p63,
normalized to background, in arbitrary units.
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Figure 32: VDR and p63 overexpression in Precursors to Squamous Cell
Carcinoma. Panels show representative images taken at a 20x magnification (scale bar =
20 μm) of normal skin, Actinic Keratosis, Acantholytic Actinic Keratosis, Acantholytic
and Hyperplastic Actinic Keratosis, Hyperplastic Actinic Keratosis, Squamous cell
carcinoma in situ and Bowenoid Actinic Keratosis from formalin fixed, paraffinembedded human skin stained for p63 and VDR.
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Figure 33: Quantitation of VDR and p63 overexpression in Precursors to Squamous
Cell Carcinoma. Quantitation of p63 (A) and VDR (B) levels from 49 normal skin
samples, 6 Acantholytic Actinic Keratosis samples, 22 Actinic Keratosis samples, 10
Actinic Keratosis Acantholytic Hyperplastic samples, 15 Hyperplastic Actinic Keratosis

79

samples, 4 Squamous cell carcinoma in situ samples and 2 Bowenoid Actinic Keratosis
samples are plotted. Y-axis represents the mean fluorescent intensity, normalized to
background, in arbitrary units. Error bars represent standard error. *= p ≤ 0.05 compared
to normal skin.
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expression in all three of SCC subtypes (SCC-Superficial, Perineural Invasion SCC and
SCC) when compared to normal skin (Figure 34 and Figure 35). Intriguingly, the
superficial squamous cell carcinoma examined showed an increase in p63 and VDR
expression compared to non-superficial SCC (Figure 35), indicating that the more
invasive cancers have reduced levels of p63 and VDR. Although all subtypes of BCC
showed a significant increase in p63 and VDR levels when compared to normal skin,
nodular basal cell carcinomas (NBCC), superficial basal cell carcinomas (SBCC) and
nodular and infiltrative basal cell carcinoma (NIBCC) expressed higher levels of p63 and
VDR compared to infiltrative basal cell carcinomas (BCCI) (Figure 36 and Figure 37).
Taken together, these results demonstrate a concomitant increase in both p63 and VDR
levels in non-melanoma skin cancers, suggesting that increased levels of p63 and VDR
might be responsible for increased proliferation upon exposure to VD3 in non-melanoma
skin cancer.
I. Mutant p53 alleles H179Y and R282W positively regulate ΔNp63α
Previously, mutant p53 was shown to interact with VDR and alter the
transcriptional activity of VDR promoting tumorigenesis (Stambolsky et al., 2010). Our
data shows that VDR increases the expression of the Np63 oncogene. Since, mutant
p53 can determine the transcriptional activity of VDR and VDR positively regulates
Np63, I wanted to determine the role of mutant p53 in VDR mediated increase in
Np63 expression (Stambolsky et al., 2010). Several studies have shown that mutant
p53 down-regulates Np63 activity leading to increased tumorigeneis
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Figure 34: VDR and p63 overexpression in different subtypes of Squamous Cell
Carcinoma. Panels show representative images taken at a 20x magnification (scale bar =
20 μm) of normal skin, SCC-Superficial, SCC from AK background, Perineural Invasion
SCC and SCC from formalin fixed, paraffin-embedded human skin stained for p63 and
VDR.
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Figure 35: Quantitation of VDR and p63 overexpression in different subtypes of
SCC. Quantitation of p63 and VDR levels from 49 normal skin samples; 13 SCCSuperficial samples, 3 Perineural Invasion SCC samples and 37 SCC samples are plotted.
Y-axis represents the mean fluorescent intensity, normalized to background, in arbitrary
units. Error bars represent standard error. *= p ≤ 0.05 compared to normal skin.
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Figure 36: VDR and p63 are overexpressed in different subtypes of Basal Cell
Carcinoma. Panels show representative images taken at a 20x magnification (scale bar =
20 μm) of normal skin, BCC-Infiltrative, BCC-Nodular, BCC- Nodular and Infiltrative
and BCC-Superficial from formalin fixed, paraffin-embedded human skin stained for p63
and VDR.
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Figure 37: VDR and p63 show significant overexpression in different subtypes of
Basal Cell Carcinoma. Quantitation of p63 and VDR levels from 49 normal skin
samples, 4 BCC-Infiltrative samples, 29 BCC-Nodular samples, 6 BCC- Nodular and
Infiltrative samples and 15 BCC-Superficial samples are plotted. Y-axis represents the
mean fluorescent intensity, normalized to background, in arbitrary units. Error bars
represent standard error. *= p ≤ 0.05 compared to normal skin.
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(Shaulian et al., 1992; Gaiddon et al., 2001; Li, Y. & Prives, 2007; Adorno et al., 2009;
Liu et al., 2009; Marine & Berx, 2009; Muller et al., 2009; Rokaeus et al., 2010;
Girardini et al., 2011; Neilsen et al., 2011; Neilsen et al., 2013). Mutant p53 regulation of
VDR transcriptional activity could represent a novel mechanism by which mutant p53
regulates Np63 expression. To determine if mutant p53 up-regulates Np63, I
studied effects of p53 knockdown in HaCaT cells that harbor two mutant alleles of p53 at
H179Y and R282W, these two mutant alleles are known to increase proliferation and
chemo-resistance, respectively (Mueller et al., 2001; Yang, D. et al., 2007; Li, X. et al.,
2012; Xu et al., 2014). As expected, cells transfected with siRNA against p53 showed a
significant reduction in p53 expression (Figure 38). As shown in Figure 38, loss of
mutant p53 in HaCaT cells also led to a concomitant reduction of both Np63 transcript
and protein levels. To confirm that loss of mutant p53 reduces Np63 levels, I silenced
p53 with siRNA specific to p53 and measured changes in p53 and Np63 protein via
immunofluorescence. Consistent with immunoblot analysis, immunofluorescence
staining of Np63 following loss of p53 showed a reduction in Np63 expression
(Figure 39). Taken together, these data indicate that the loss of mutant p53 leads to a
reduction in Np63 transcript and protein expression.
Since mutant p53 was shown to regulate the activity of VDR, I next examined the
effect of the combined loss of both VDR and mutant p53 on Np63 levels. I transfected
HaCaT cells with non-silencing control siRNA or siRNA against p53 and VDR alone or
together. Following transfections I measured the change in Np63, VDR and p53
protein expression via immunoblot analysis. As expected and previously shown in Figure
8, loss of VDR leads to a dramatic reduction in Np63 protein expression (Figure 40A).
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Figure 38: Loss of mutant p53 led to a reduction in ΔNp63α levels. HaCaT cells were
transfected with non-silencing control siRNA and siRNA against p53. Changes in
transcript (Top panel) and protein (Bottom panel) expression of p63 and p53 were
measured by qRT-PCR (*=p values ≤ 0.05) and immunoblot analysis, respectively. RNA
levels were measured with assays on demand (AODs) specific to p63, p53 and GAPDH.
GAPDH was used as an endogenous control. Protein expression was detected using p63
and p53 specific antibodies. Detection of β-actin with a β-actin specific antibody was
used as a loading control. The fold-change in protein levels, relative to NSC transfected
cells, is listed above each band.
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Figure 39: Mutant p53 is important for ΔNp63α protein expression. Top panel:
HaCaT cells were transfected with non-silencing control siRNA and siRNA against p53
followed by detection of p63α and p53 by immunofluorescence. Bottom panel: average
mean fluorescent intensity of immunofluorescence staining for p63 and p53 in HaCaT.
Error bars represent standard error of the mean. *=p values ≤ 0.05 compared to vehicle
control cells. Each sample consists of a 100 counted cells per experiment.
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Additionally, loss of mutant p53 did not only decrease Np63 levels but also reduced
VDR protein expression when compared to NSC transfected samples (Figure 40A). The
combined knockdown of VDR and mutant p53 together further reduced Np63 protein
expression when compared to cells transfected with siRNA against p53 or VDR alone
(Figure 40A). Having established that mutant p53 and VDR up-regulates Np63 protein
expression, I next wanted to determine if mutant p53 in cooperation with VDR upregulates Np63 transcript levels. To this end, I again knocked down the expression of
VDR and p53 expression alone or together and measured changes in p63, VDR and p53
transcript level by qRT-PCR. As expected, there was a significant reduction in mutant
p53 transcript levels following transfection with siRNA against p53 (Figure 40B).
Knockdown of mutant p53 resulted in a reduction in p63 transcript levels in HaCaT cells
(Figure 40B) indicating that mutant p53 may be regulating Np63 at the transcript
level. Consistent with previous findings, loss of VDR led to a reduction in both p63 and
VDR transcript levels (Figure 40B). Knockdown of p53 and VDR together led to a
significant decrease in both mutant p53 and VDR transcript levels (Figure 40B).
Combined knockdown of both mutant p53 and VDR together did not further reduce p63
transcript levels beyond those observed with individual VDR or mutant p53 knockdown,
suggesting that mutant p53 may up-regulate Np63 expression at both the transcript
and protein levels via VDR.
J. Mutant p53 forms a complex with VDR
Previously, the mutant p53 allele R175H was shown to form a complex with VDR
(Stambolsky et al., 2010). The interaction between VDR and mutant p53 was shown to
reside in the DNA binding domain (DBD) of mutant p53 R175H
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Figure 40: Loss of mutant p53 and/or VDR reduced ΔNp63α protein and transcript
expression. HaCaT cells were transfected with control siRNA, or siVDR, sip53 or both
sip53 and siVDR. Changes in protein (A) and transcript (B) levels of Np63, VDR and
p53 were measured by immunoblot and qRT-PCR analysis, respectively. The fold-change
in protein levels, relative to NSC transfected cells, is listed above each band.
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(Stambolsky et al., 2010). The binding of mutant p53 to VDR was shown to alter
VDR/VD3 nuclear signaling, resulting in changes in gene expression such as Mitogen
Activated Protein Kinase Kinase 5 (MAP2K5) and Fibroblast Growth Factor Receptor 2
(FGFR2) (Stambolsky et al., 2010). I chose to evaluate whether the mutant p53 H179Y
and R282W alleles, both commonly associated with UV radiation (Dumaz et al., 1993;
Ziegler et al., 1993), form a complex with VDR to increase the expression of Np63. I
performed immunoprecipitation studies wherein I immunoprecipitated mutant p53 and
measured co-precipitation of VDR by immunoblot analysis in HaCaT cells. As expected,
immunoprecipitation with a p53 specific antibody showed precipitation of mutant p53
from HaCaT cells, while immunoprecipitation of mutant p53 also led to co-precipitation
of VDR (Figure 41). This data indicates that mutant p53 H179Y or R282W alleles or
both in combination form a complex with VDR.
K. Mutant p53 plays a role in VD3-mediated increase in Np63
Since, mutant p53 has been implicated in VDR target gene regulation in the
presence of VD3 (Stambolsky et al., 2010) and I have shown that VDR and VD3 increase
Np63 expression, I next examined the role of mutant p53 on VD3 mediated upregulation of Np63. To address this I measured changes in Np63 protein levels by
immunoblot analysis following treatment with vehicle control, 10 nM VD3 or 100 nM
VD3 for 24 hours in presence or absence of mutant p53 knockdown. As expected, 10 nM
VD3 increased Np63 protein levels in HaCaT and HaCaT II-4 cells transfected with
NSC (Figure 42). Consistent with previous reports from our laboratory, expression of
VDR increased in a dose dependent manner following VD3 treatment in HaCaT cells
(Kommagani et al., 2006; Kommagani et al., 2009) (Figure 42A). Both doses of VD3 also
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Figure 41: Endogenous VDR forms a complex with endogenous mutant p53. HaCaT
cells were grown to 90% confluency. Whole extracts from HaCaTs were subject to
immunoprecipitation with a p53 specific antibody or myc-tag antibody as a control
followed by immunoblot analysis to detect p53 and VDR expression with antibodies
specific to p53 and VDR.
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Figure 42: Knockdown of mutant p53 (H179Y and R282W) reduced VD3-mediated
increase in ΔNp63α expression. HaCaT (A) and HaCaT II-4 (B) cells were transfected
with non-silencing control siRNA or siRNA against p53 followed by treatment with
vehicle control, 10 nM or 100 nM VD3 for 24 hours. The change in Np63, p53 and
VDR was measured by immunoblot analysis. The fold-change in protein levels, relative
to cells treated with vehicle control following transfection with NSC is listed below each
band.
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led to an increase in VDR protein expression in HaCaT II- 4 cells (Figure 42B). HaCaT
and HaCaT II-4 cells transfected with siRNA against p53 showed a significant reduction
in mutant p53 levels as expected, which coincided with a reduction in Np63
expression in these two cell lines, regardless of VD3 treatment (Figure 42). Furthermore,
loss of mutant p53 also reduced VD3 mediated stabilization of VDR (Figure 42),
indicating that mutant p53 is also involved in regulating VDR expression. Mutant p53
regulation of VDR is potential mechanism by which mutant p53 indirectly up-regulates
Np63. Taken together, our data suggests that mutant p53 is important for VD3mediated increases in Np63 protein levels.
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IV. DISCUSSION
A. VDR and 1, 25-dihydroxyvitamin D3 up-regulate Np63 protein expression
and activity via Akt and p38 MAPK activation.
Proliferation followed by simultaneous differentiation and inhibition of
proliferation are noteworthy characteristics of the skin, allowing for the development of
each layer of the epidermis (Fuchs & Raghavan, 2002). Delineating the mechanisms
involved in activating or preventing keratinocyte proliferation remains critical for
improving our understanding of non-melanoma skin cancer (NMSC). Np63 is the
most robustly expressed p63 isoform in the basal layer of the skin, where Np63 is
known to up-regulate genes involved in proliferation (Yang, A. et al., 1998; Mills et al.,
1999). In fact, Np63 is considered to be the master regulator of epithelial stemness,
and it is likely involved in multiple pathways that stimulate proliferation (Melino et al.,
2015). Overexpression of Np63 is seen in many non-melanoma skin cancer lesions,
such as the lesions found in squamous cell carcinoma (Choi et al., 2002; Di Como et al.,
2002; Bircan et al., 2006; Sakiz et al., 2009). Despite its broad role in controlling
epithelial fate, very little is known about the upstream regulators of Np63.
Our laboratory has previously shown that Np63 positively regulates VDR
expression (Kommagani et al., 2006). VDR is expressed in the basal layer of the skin and
is well known for its role in differentiation and calcium homeostasis (Dusso et al., 2005;
Haussler et al., 2012). Previous work showed that VDR functions independently of VD3
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to activate basal level transcription of 24-hydroxylase (Ellison et al., 2007). Here I show
that VDR is essential for maintaining basal levels of Np63 transcription in a ligand
independent manner, thus suggesting that VDR may initiate proliferation indirectly
through Np63 (Figure 8).
VD3 has been considered a chemotherapeutic adjuvant in the treatment of a
number of cancers (Asagami et al., 1996; Zhao et al., 1997; Iseki et al., 1999; Reis-Filho
et al., 2002; Lo Muzio et al., 2005; Bircan et al., 2006; Cheng et al., 2009). Our study
indicates that reduction in Np63 levels could improve the therapeutic potential of VD3
in the treatment of non-melanoma skin cancers. This notion is supported by previous data
demonstrating that Np63 confers cisplatin resistance in a number of cancers such as
head and neck squamous cell carcinomas and breast cancers (DeYoung et al., 2006;
Leong et al., 2007; Sen et al., 2011), thus suggesting that controlling Np63 levels may
be beneficial in treating epithelial cancers (DeYoung et al., 2006; Leong et al., 2007; Sen
et al., 2011)
Therapeutic potential of low dose VD3
Low levels of VD3 has been shown to correlate with high-grade prostate cancer in
men over 55 years of age (Schenk et al., 2014), indicating that low levels of VD3 may
have a profound effect on cancer progression. Our findings herein suggest a novel role
for VDR/VD3 in regulating proliferation and cell survival through the regulation of
Np63. I found that VD3 increases the expression of Np63 transcript and protein in
the presence of its receptor VDR (Figure 11) and increases keratinocyte proliferation
(Figures 11 and 20), but only at low doses of VD3. This finding mirrors the observed role
for VD3 in prostate cancer, which has shown that low levels of VD3 increase prostate
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tumor cell proliferation and suggests that low-levels of VD3 may mediate the resulting
downstream increase in proliferation through its effects on Np63 (Figure 20). Our data
suggest that low levels of VD3 may enhance cancer progression, suggesting the level of
VD3 is extremely important in eliciting the appropriate response as a chemotherapeutic
adjuvant.
Therapeutic potential of high dose VD3
High levels of serum VD3 are associated with a decreased risk of breast cancer
and colon cancer mortality (Anic et al., 2014; Kim & Je, 2014; Zgaga et al., 2014;
Weinstein et al., 2015). Moreover, high level VD3 therapy has been used as a
chemotherapeutic adjuvant for patients with prostate cancer (Zhuang & Burnstein, 1998).
Here I show that high doses of VD3 do not increase Np63 levels and correlate with a
reduction in cell proliferation (Figure 11 and Figure20). Consequently, the ligand
requirement of VDR mediated transcription might be situation specific allowing VDR to
up-regulate genes essential for cell homeostasis in the presence or absence of VD3,
thereby providing an additional layer by which keratinocyte proliferation is sustained in
response to varying environmental settings.
Non-genomic contributions of VD3 to Np63 function
VDR and VD3 up or down-regulate many transcriptional targets and cellular
processes. VDR and VD3 have non-genomic functions known as rapid response activities
in the cell which include insulin secretion, smooth muscle migration and opening calcium
and chloride channels (Haussler et al., 2011). VD3 has also been shown to activate a
number of kinases such as Akt, Protein kinase A (PKA) and Protein Kinase C (PKC)
through the rapid response-signaling pathway (Zhang, Y. et al., 2006; Deeb et al., 2007;
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Zhang, X. & Zanello, 2008; Haussler et al., 2011). Here I demonstrate that VD3 enhances
Np63 expression in a non-genomic manner by activating p38 MAPK thereby
increasing Np63 protein levels (Figure 17, Figure 18 and Figure 19). This increase in
Np63 protein levels was shown to be dependent on VD3 concentration as only low
doses of VD3 were able to increase Np63 levels (Figures 10-12). Increased Np63
protein induced by low doses of VD3 also correlated with an increase in cellular
proliferation in keratinocytes (Figure 20), thus implicating low level VD3 as an mediator
of the increased proliferation seen in cancer cells. Interestingly, knockdown of Np63
or VDR reduced cell proliferation at all doses of VD3 tested (Figure 24).
Upstream regulators of the VD3 /Np63 pathway
Previous reports have shown VD3 can activate the AKT pathway, a wellestablished survival pathway (Zhang, Y. et al., 2006; Zhang, X. & Zanello, 2008).
Moreover, AKT has been reported to positively regulate the expression of Np63
(Segrelles et al., 2006; Ogawa et al., 2008). Our lab previously reported that Np63
represses PTEN transcription leading to increased AKT activity (Leonard et al., 2011).
Here I show that both AKT and VDR plus VD3 contribute to the regulation of Np63
protein expression (Figure 16). Furthermore, inhibition of Akt reduced the VD3-mediated
increase in keratinocyte proliferation, which correlated with the effects on Np63
protein level (Figure 25). Our data supports the finding that VD3 increases Akt activation,
but that this increase is not the sole mechanism that leads to increased Np63 protein
levels. While Akt plays a major role in the regulation of basal Np63 levels, VD3mediated increases in Akt activation only play a minor role in the regulation of Np63
protein.
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Previous findings have shown that VD3 activates the MAP kinase p38 in a nongenomic pathway leading to the increased proliferation of muscle cells (Buitrago, C. G. et
al., 2006; Buitrago, C. & Boland, 2010). VD3 was shown to bind to VDR in a complex
with caveolin-1 at the plasma membrane to stimulate a non-genomic VD3 response
(Buitrago, C. & Boland, 2010). Once VD3 binds to membrane associated VDR and
caveolin-1, VDR recruits the tyrosine kinase Src for full activation of p38 MAPK
(Buitrago, C. & Boland, 2010). Activated p38 MAPK has also been shown to lead to an
increase in Np63 protein (Cheng et al., 2009). In my study, I show that inhibition of
p38 MAPK activation eliminates low dose VD3-mediated increases in Np63 (Figure
18 and Figure 19). COX-2, a target of p38 MAPK, is also up-regulated in non-melanoma
skin cancer, which further supports a role for activated p38 MAPK in these cancers and
shows that p38 MAPK can up-regulate its target genes, such as Np63 shown here
(Bachelor & Bowden, 2004). Our data indicates that inhibition of p38 MAPK partially
abrogates the observed VD3-mediated increases in Np63 suggesting that p38 MAPK is
a potential pathway to target in conjunction with current chemotherapeutic regimen in
cancers such as NMSC.
VD3 and Np63 expression in non-melanoma skin cancers
Both VDR and p63 have been separately shown to be overexpressed in nonmelanoma skin cancers (Hibi et al., 2000; Choi et al., 2002; Di Como et al., 2002;
Mitschele et al., 2004; Reichrath et al., 2004; Bircan et al., 2006; Sakiz et al., 2009). In
this study, I demonstrated that both p63 and VDR expression are increased in the same
tissues of patients with BCC, SCC or precursor lesions to SCC (Figure 29). Interestingly,
only VDR was overexpressed in actinic keratose (AK) and only Np63 protein showed

101

an increase in acantholytic and hyperplastic actinic keratose (AKAH) (Figure 32). Since
VDR positively regulates Np63 expression, it is feasible that the onset of AK
promotes the expression of VDR, which in turn induces Np63 expression as lesions
progress toward SCC. Alternatively, it could be argued that overexpression of Np63
positively regulates VDR expression resulting in the induction of AKAH, consistent with
AKAH being a thicker and more proliferative lesion compared to AK (Goldberg et al.,
1994). In this scenario, the initial Np63 leads to increased VDR expression as the
lesion progresses to SCC. Given the role of p63 and VDR in the inhibition of cell
invasion, it came as a surprise that both VDR and p63 were highly expressed in the more
invasive SCC tumor samples compared to the SCC precursor samples (Figure 34).
Mutant p53 was previously shown to inhibit the p63-mediated reduction in cell migration
and invasion (Girardini et al., 2011; Liu et al., 2011; Neilsen et al., 2013). Furthermore,
mutant p53 can selectively alter the transcriptional activity of other transcription factors
leading to phenotypic changes that promote tumorigenesis (Stambolsky et al., 2010;
Girardini et al., 2011; Liu et al., 2011; Neilsen et al., 2013). In my study, I found that
VDR led to increased levels of Np63, which also correlated with tumor progression.
Mutant p53 is highly expressed in many NMSC lesions and inhibits Np63 function,
and should therefore serve to increase the invasive properties of SCC. Consistent with
previous reports that p63 is increased in BCC (Hibi et al., 2000; Choi et al., 2002; Di
Como et al., 2002; Mitschele et al., 2004), I similarly found that p63 is increased in BCC
and this increases correlates with an increase in VDR in these tumors (Figure 36).
These results imply that elevated levels of VDR are not an indication of a good
prognostic outcome since I observed higher levels of VDR in more invasive SCC
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samples. Therefore, increased Np63 and VDR expression in NMSC may serve as
biomarkers for these types of cancers. Np63 and VDR expression could also be used
as predictors of the patient response to VD3 treatment as a chemotherapeutic agent only
or in conjunction with other chemotherapeutic treatments. VDR and VD3, which are both
considered important in cancer prevention, are shown here to also play a role in the
regulation of oncogenic Np63 which correlates with an increase in keratinocyte
proliferation at low VD3 concentration, bringing to light a potential problem with the use
of VD3 in cancer prevention and treatment (Audo et al., 2003; Bikle et al., 2006).
Together, these results suggest that VD3 can play a growth stimulatory role in the
presence of VDR in keratinocytes cells by regulating the expression of Np63. Our data
suggests that monitoring VD3 concentration in cancer treatment regimens will be critical
to reduce cancer cell growth.

This finding is reinforced by a recent study which

demonstrated that tumors from SKH-1 showed an increase in p63 expression with
increasing concentration of dietary vitamin D (Hill et al., 2014). Since VD3 action
appears to be dose-dependent, ensuring high enough doses of VD3 are getting into the
tumor cells to reduce Np63 expression and the resulting proliferation will be critical to
its successful implementation as a chemotherapeutic adjuvant.
B. VDR/VD3 mediated up-regulation of Np63 expression is dependent on mutant
p53.
Previous studies have shown that vitamin D supplementation protects against skin
cancer (Garland et al., 2009; Ness et al., 2015). UVB radiation with a wavelength of
290-330 nM is required for VD3 production in the skin (Garland et al., 2009; Bikle, 2012;
Ness et al., 2015), yet ultraviolet (UV) is the major cause of skin cancer (Bikle, 2012;
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Gordon, 2013; Surdu, 2014). Interestingly, this is the same wavelength of radiation that
induces many of the mutations found in the p53 gene (Dumaz et al., 1993; Ziegler et al.,
1993). In the skin UVB irradiation leads to the production of thymine-thymine dimer,
which are a cys-syn cyclobutane pyrimidine dimer that arise from a cytosine to thymine
substitution induce by the UVB energy (Dumaz et al., 1993; Ziegler et al., 1993). A
number of these UV induced mutations are found in the p53 gene in non-melanoma skin
cancer (Ziegler et al., 1993). Since p53 is highly mutated in skin cancer and nonmelanoma skin cancers show an increased level of Np63, it is vital to determine the
interplay between the two proteins in skin cancer.
Role of mutant p53 in the regulation of the VD3/Np63 pathway
Mutant p53 function is dependent on the specific mutation. While some mutant
p53 proteins lead to loss of function, some lead to gain of function and others function
similar to wild type p53 (Freed-Pastor & Prives, 2012). Defining the mechanism of action
of each mutant p53 allele remains an important task to understand underlying role each
plays in cancer. Previous work has shown an interplay between VDR and p53 R175H
(Stambolsky et al., 2010) but the p53 R175H is not a mutant that arises from a cytosine to
thymidine C-T transition, which is a characteristic of UV induced mutations. In fact, the
p53 R175H is a G-A mutation, which is commonly induced in cancer to eliminate the
CpG methylation site in the p53 gene or is a result of an unrepaired mutation that was
substituted with an adenosine during replication (Dumaz et al., 1993; Ziegler et al.,
1993). To better understand mutant p53 proteins arising from UVB damage, I evaluated
mutant p53 function in HaCaT cells carrying two mutant p53 alleles, H179Y (resulting
from CC to TT mutation) and R282W (resulting from a C to T mutation) (Dumaz et al.,
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1993; Ziegler et al., 1993). I found that loss of mutant p53 significantly reduced Np63
expression levels (Figure 38) and loss of Np63 resulted in a decrease in keratinocyte
proliferation (Figure 23). Conversely, I also showed that the mutant alleles of p53 and
VDR positively regulate Np63 expression (Figures 39), potentially via mutant p53
modulation of VDR regulation of Np63 as described earlier (Stambolsky et al., 2010).
Based on our data, however, it is unlikely that mutant p53 solely increases Np63
transcript levels (Figure 40). Loss of mutant p53 in the absence of VDR also led to a
further reduction in Np63 protein levels compared to the loss of mutant p53 or VDR
alone (Figure 40). Thus indicating that mutant p53 in the presence of VDR up-regulates
Np63 at the protein level potentially through the stabilization of Np63 protein as
the combined knockdown of mutant p53 and VDR did not lead to a further reduce in p63
transcript. Moreover, I found that mutant p53 was important for VD3-mediated increase
in Np63 (Figure 42).
The interaction between VDR and mutant p53 leads to changes in VDR target
transactivation wherein p53 R175H increases the expression of genes involved in
proliferation and cell survival but inhibits pro-apoptotic genes (Stambolsky et al., 2010).
Here I show that p53 H179Y and/or R282W proteins form a complex with VDR (Figure
41). This complex might have the ability to increase the expression of Np63. In
NMSC, Np63 expression has been shown to increase tumor proliferation (Leonard et
al., 2011; Leonard et al., 2013; Li, C. et al., 2013; Ripamonti et al., 2013), consistent
with our data which showed that loss of Np63 leads to a decrease in keratinocyte
proliferation (Figure 23). Interestingly, the overexpression of mutant p53 H179Y allele
has been shown to increase human embryonic lung fibroblast proliferation by promoting
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the expression of cyclin A1 and cyclin dependent kinase 4 (CDK4) (Yang, D. et al.,
2007). Increased mutant p53 and increased Np63 expression in the presence of VDR
and VD3 led to increased keratinocyte proliferation. Furthermore, mutant p53 alleles
H179Y and R282W were critical for the VD3-mediated increase in Np63 expression in
keratinocytes (Figure 42), indicating a potential interplay between VDR/VD3 signaling,
mutant p53 signaling and Np63 signaling that could play a major role in the onset of
NMSC and many other cancers of epithelial origin.
Other potential mediators of VD3/Np63 pathway in the presence of mutant p53
VDR and VD3 have rapid response signaling that occur independently of
transcription, so mutant p53 could induce the activation of specific kinases which
stabilize Np63 protein expression such as p38 MAPK, cAbl and Akt (Zhuang &
Burnstein, 1998; Zhang, Y. et al., 2006; Zhang, X. & Zanello, 2008; Yuan et al., 2010;
Haussler et al., 2011) by modulating VD3 rapid response signaling cascades, although
further testing is required to confirm this hypothesis.
Previous reports suggest that mutant p53-mediated increase in Np63 lead to a
corresponding increase in the expression of Heat Shock Protein 70 (HSP70) and a
resulting stabilization of mutant p53 expression (Wu et al., 2005; Wiech et al., 2012).
Furthermore, evidence in the kidney suggests that VDR potentially up-regulates HSP70
expression (Garcia et al., 2014), raising the possibility that VDR could increase HSP70
indirectly through VD3/VDR-mediated increases in Np63 expression (Figure 11)
leading to increased mutant p53 expression and tumorigenesis.
Potential interactions of VD3 with p53 and Mdm2
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Not all tumors carry a p53 mutation; some express wild type p53 while other
tumors show loss of wild type p53 expression all together (Stambolsky et al., 2010;
Freed-Pastor & Prives, 2012). The complete loss of p53 expression by deletion of the
gene or epigenetic change to the gene locus (Thompson et al., 1992) frequently arises in
cancer. As shown in Figure 8, loss of VDR in the presence of wild type p53 led to a
reduction in Np63 transcript and protein expression, but wild type p53 expression was
very low in these primary keratinocyte cells. When wild type p53 is stabilized as a result
of a stressor, the stability of Np63 protein expression in this environment will result in
a balance between wild type p53 mediated reduction in Np63 and VDR/VD3-mediated
increase in Np63 (Galli et al., 2010).
Wild type p53 leads to Np63 degradation by increasing the level of Mdm2,
which binds to Np63 and causes its translocation to the cytoplasm (Galli et al., 2010).
Translocation of Np63 to the cytosol brings Np63 in close proximity to the E3ubiquitin ligase Fbw7 for degradation (Galli et al., 2010). Interestingly, VD3 also
enhances Fbw7 ubiquitination, but this enhanced activity was only shown at 100 nM
VD3, and 100 nM of VD3 did not increase Np63 expression in our keratinocyte study
(Figure 11) (Fekrmandi et al., 2015). The level of VD3 in cells could be the driver that
initiates cell proliferation or differentiation, cell cycle arrest or apoptosis. Tumor
proliferation could be enhanced as a result of a tumor cell reducing the concentration of
VD3 in a cell to promote proliferation via increased Np63 and reduce wild type p53
levels by up regulating Mdm2 (Haupt, Y. et al., 1997). VDR and VD3 increase Mdm2
levels only the presence of wild-type p53 (Fekrmandi et al., 2015). Therefore, in the
presence of wild type p53 and low VD3, a reduction in wild p53 occurs through Mdm2,
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thus leading to the VDR and VD3-mediated increase in Np63 expression and the
observed enhancement in proliferation.
Potential mechanism of VDR mediated increase in Np63 in p53-null cells
Tumors that are p53-null can still induce many of the functions of wild-type p53
harboring tumors due to the presence of p73. p73, a member of the p53 family, has
distinct functions in neuronal development, proliferation and tumor suppression (Roos &
Kaina, 2006). Like Np63, TAp73 and TAp73β increase the expression of VDR in
p53 wild type cells and p53-null cells (Kommagani et al., 2007). TAp73 and TAp73β
also induces the intrinsic apoptotic pathway by increasing the expression of PUMA,
leading to Bax activation and cytochrome C release from the mitochondria (Roos &
Kaina, 2006). Thus, it is likely that in a p53-null tumor, the balance between proliferation
and cell death is mediated by p73. Our findings suggest that increased TAp73 and
TAp73β potentially leads to increases in Np63 via the increased expression of VDR in
both cells that express wild type p53 or are null for p53. Unfortunately, Np63 has
been shown to inhibit TAp73 activity and thereby apoptosis (Roos & Kaina, 2006).
Interestingly, treatment with DNA damage inducing agents like etoposide not only
increases p73 message via E2F1 but also stabilizes p73 expression via activation of Chk2
(Roos & Kaina, 2006). Following activation, the Chk2 upstream regulator ATM
phosphorylates Np63 leading to degradation of Np63 (Matsuoka et al., 1998).
More importantly, increased Np63 expression leads to an increase in the expression
levels of ATM (Craig et al., 2010). Therefore, in a cell lacking p53, p73 would be
expected to lead to increased VDR expression and a corresponding increase in Np63,
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which would either inhibit p73 pro-apoptotic activity or increase ATM levels thereby
leading to its own degradation.
C. Conclusions
VDR and VD3 play a central role in cancer through modulation of cell
survival and apoptosis (Deeb et al., 2007). The work presented in this dissertation
elucidated multiple novel mechanisms by which VD3 and VDR function to increase
Np63 protein expression (Figure 43). I showed that VDR increases Np63
expression. I also found that low doses of VD3 cause an increase in Np63 protein in a
dose dependent manner up to 10 nM VD3 (Figure 10) leading to increased keratinocyte
proliferation. I further showed that VDR-mediated increases in Np63 are critical for
VD3-mediated increases in proliferation, thus advancing our understanding of the
mechanism by which VDR and VD3 lead to increased keratinocyte proliferation. Further,
I showed that both p38 MAPK and Akt modulate VD3-mediated increases in Np63
and the downstream increase in cell proliferation. The interplay between VDR and
mutant p53 showed that not only dose VDR play an important role in VD3 mediated
increase in Np63 but mutant p53 expression was important as well. Interestingly, both
Np63 and VDR levels were increased in NMSC samples compared to controls
indicating a potential interplay between VDR and Np63 function that leads to an
increase in cancer cell survival.
It has become increasingly clear we in the VD3 field still have a rudimentary
understanding of the interplay between p53, Np63 and VD3/VDR pathways and how
they play off each
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Figure 43: VDR/VD3 mediated regulation of Np63. VD3 stimulates cell growth in
the presence of VDR with (A) or without (B) mutant p53 complex in keratinocytes cells
by regulating the expression of Np63 via Akt and p38. 1 (Kommagani et al., 2006), 2
(Barbieri et al., 2003), and 3 (Cheng et al., 2009).
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other to promote tumor cell survival or lead to tumor cell death. Delineating the interplay
between multiple pathways is critical to our understanding of cancer progression,
metastasis and chemoresistance.
D. Concluding remarks
VD3 deficiency is associated with increased risk of cardiovascular disease,
hypertension, stroke, diabetes, multiple sclerosis, rheumatoid arthritis, macular
degeneration, mental illness, chronic pain and cancer (Cannell & Hollis, 2008). The
preferred method to treat VD3 deficiency is supplementation with 25-hydroxy-vitamin D
(25(OH)D) or pre-VD3 (cholecalciferol) (Cannell & Hollis, 2008). Our data and others
suggest that the level of VD3 is critical to induce the preferred response such as
prevention of cancer. For example, in certain cancers high serum levels of VD3 such as
≥95 nmol/L were sufficient to reduce colon cancer risk by 55% compared to 40 nmol/L
(Freedman et al., 2007). Furthermore, lower levels of serum VD3, those less than 50
nmol/L in patients with breast cancer are linked with increased metastases and a reduced
survival rate (Garland et al., 2009). Thus, 25-hydroxy-vitamin D levels (serum VD3) and
maintaining a sufficient level of serum VD3 is important when considering the
appropriate concentration of VD3 for supplementation. The recommended serum VD3
level is 30 nmol/L to 50 nmol/L, which is generally achieved by 600 international units
(IU) of supplemented cholecalciferol or daily UVB exposure (Ross et al., 2011).
Unfortunately, the recommended level of serum VD3 does not prevent or reduce
mortality in colon, breast, or prostate cancer (Freedman et al., 2007; Gorham et al., 2007;
Garland et al., 2009). Furthermore, UVB exposure has the potential to promote
melanoma and non-melanoma skin cancers.
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Extremely high levels of serum VD3 can be toxic and lead to hypercalcemia.
Hypercalcemia is an increase in serum calcium that if left untreated will lead to
calcification of internal organs like the kidneys (Cannell & Hollis, 2008). Fortunately, for
practitioners this is rarely ever a problem due to the time (months) and dose (≥10,000
IU/day) of cholecalciferol that is required to induce hypercalcemia (Cannell & Hollis,
2008). More recently Durup et al., identified a correlation between serum VD3 levels of
≥125 nmol/L and increased risk of coronary artery disease and stroke (Durup et al.,
2015). Indicating that there is a narrow range at which VD3 is beneficial, for cancer
prevention greater than 95 nmol/L and to prevent heart disease less than 125 nmol/L.
Therefore, based on our data and the literature in the field the recommended
serum level of VD3 should be increased and kept in a narrow range between 100 and 120
nmol/L. As such, vitamin D supplementation should be closely monitored to ensure the
level does not drop or rise beyond a level that is advantageous to the patient.
E. Future Directions
This dissertation defines a novel mechanism for Np63 regulation in response to
VDR and VD3 genomic and non-genomic signaling.

My findings suggest VD3

concentration is a central driver of cell survival in NMSC. Since our data shows that low
VD3 levels increase Np63 and keratinocyte proliferation (Figure 11), the next step for
this project is to determine the mechanism by which high dose VD3 leads to decreased
keratinocyte proliferation. A better understanding of high dose VD3 mechanism of action
can lead to new more potent treatments that can be specifically exploited to combat
certain cancer. Here I observe a reduced rate of proliferation with high dose VD3 (Figure
20), thus suggesting that my data can be used translationally in the clinic to treat patients
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with NMSC using a high dose of VD3 to reduce tumor proliferation. Interestingly, both
topical VD3 and a VD3 analog that is in a locked confirmation to induce the rapid
response active of VD3, showed reduce skin tumor burden in Shk1 mice further
suggesting that VD3 can be used clinically to treat NMSC (Dixon et al., 2011). Moreover,
VD3 stabilizes the expression of VDR and VDR play an important role in inducing
differentiation and inhibition of migration, which further serves as to reduce
tumorigenesis (Palmer et al., 2001; Kommagani et al., 2006). Furthermore, VDR has
been previously shown to induce the expression of VDR target genes in a p53-dependent
manner (Fekrmandi et al., 2015). It would be interesting to see if there are genes that are
induced by VDR in Np63-dependent manner.
Understanding cancer biology has become increasingly difficult with the
identification of microRNAs (miRNA) and long non-coding RNAs (lncRNA) (Ling et
al., 2013). Future studies should focus on miRNAs induced or inhibited by the interplay
between VDR/Np63/mutant p53 at both 10 nM and 100 nM VD3 along with defining a
role for p38 MAPK and Akt in the regulation of the miRNAs. Subsequently,
identification of pathways up or down-regulated by these miRNA would help to define a
global NMSC signaling pathway including VDR and Np63.
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